

# Natural Occurrence and Chemical Synthesis of Bile Alcohols, Higher Bile Acids, and Short Side Chain Bile Acids

Mizuho UNE and Takahiko HOSHITA

*Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, 1-2-3 Kasumi,  
Minami-ku, Hiroshima, 734, Japan*

**Key words:** *Bile alcohols, Higher bile acids, Short side chain bile acids*

Both bile acids and bile alcohols, a subclass of steroids, are made from cholesterol as its major end metabolites by the liver of vertebrates. Their conjugates are the major constituents of the bile and possess a special function as an aid to intestinal lipid digestion and absorption.

The most common naturally occurring bile acids in mammals, birds, most snakes, and various teleostean fishes, are cholic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid. In addition to these  $3\alpha$ -,  $7\alpha$ -, or  $12\alpha$ -hydroxy derivatives of  $5\beta$ -cholan-24-oic acid, a number of  $5\beta$ -cholan-24-oic acids carrying a hydroxyl group at C-1, C-2, C-4, C-6, C-16, C-22, or C-23 position, a  $\beta$ -oriented hydroxyl group, or a keto group have been found in the bile, serum, urine and feces of these vertebrates.  $5\alpha$ -Cholan-24-oic acid derivatives occur as a high proportion of the bile acids in some lizards and in lesser amounts in various vertebrates.

Biles of evolutionarily primitive vertebrates such as some lizards, crocodiles, alligators, turtles, tortoises, all amphibians, certain bony fishes, sharks, and rays contain, in place of the  $C_{24}$  bile acid conjugates, other types of bile salts, sulfate esters of bile alcohols and unconjugated or taurine-conjugated bile acids with more than 24 carbon atoms (higher bile acids). Bile alcohols and higher bile acids have the  $C_{24}$  bile acid type of nuclear structure and all or part of the cholesterol type side chain in their carbon skeleton. Although the distribution of bile alcohols and higher bile acids in nature was long considered to be confined to the primitive vertebrates, it is now recognized that these compounds are accumulated in patients with inherited diseases related to abnormal cholesterol metabolism. They are present in trace amounts even in healthy humans. Furthermore, a few 4- or 5-cholen-24-oic acid derivatives and a few  $C_{22}$  and  $C_{23}$  bile acids with the shortened side chain have been found in biological fluids of healthy and diseased humans.

Several excellent reviews about the naturally occurring bile acids and bile alcohols have appeared<sup>61, 74, 75, 101, 105, 183</sup>. It should be men-

tioned, however, that there is no review covering all the known bile acids and bile alcohols including chemically synthetic derivatives. The present review is a detailed tabulation of bile alcohols, higher bile acids, and short side chain bile acids. Derivatives of  $5\alpha$ - and  $5\beta$ -cholan-24-oic acids and of 4- and 5-cholen-24-oic acids are not included in this review. Natural occurrence and chemical synthesis of these  $C_{24}$  bile acids are the subject of our forthcoming review.

## Bile Alcohols

Bile alcohols are here defined as neutral steroidal alcohols biochemically related bile acids.

Tables 1-6 list all the naturally occurring bile alcohols of established structure and most chemically derived  $C_{27}$ - $C_{22}$  bile alcohols. Artifacts formed from native bile alcohol sulfates by alkaline hydrolysis, dehydro-derivatives having no hydroxyl group, esterified derivatives, and derivatives containing other elements than oxygen, e.g. nitrogen, sulfur, or halogens, are not included in the tables. Mono- and di-oxygenated cholestane derivatives, e.g.  $7\alpha$ -hydroxycholesterol, are not listed in the tables because they are usually called sterols rather than bile alcohols. Similarly, polyoxygenated steroids found in marine invertebrates and shark-repelling and ichthyotoxic steroids obtained from some fishes are also excluded.

The trivial names of bile alcohols, isolated from the bile of vertebrates other than humans, include as a prefix part of the Latin name of the genus of the animal from which they were first isolated. When both isomers differing in the configuration at C-5 are known, the prefix  $5\alpha$  or  $5\beta$  is then used with the original name. For bile alcohols with epimeric hydroxyl groups for which there is no accepted trivial name, the prefix "epi" is used preceded by a number and a hyphen, indicating the position at which the epimeric hydroxyl group is present, e.g. 3-epimyxinol. For deoxy derivatives, the prefix "deoxy" will be used, preceded by a number and a hyphen, indicating the place where the hydroxyl group is missing,

e.g. 26-deoxy-5 $\beta$ -ranol. Bile alcohols found only in the biological fluids of humans and unnatural

bile alcohols have no trivial names; they are usually designated their systematic names.

**Table 1.** Hexa-oxygenated C<sub>27</sub> bile alcohols

No.	Systematic name (Trivial name)	Natural source <sup>a</sup>	Synthetic source <sup>b</sup>
0101	5 $\beta$ -Cholestane-2 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26,27-hexol (Arapaimol-B)	<i>Arapaima gigas</i> <sup>78)</sup>	— <sup>c</sup>
0102	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 24, 25-hexol	CTX-U <sup>226)</sup>	—
0103	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25, 26-hexol	Human-U <sup>82, 83)</sup> , -S <sup>84)</sup> ; CTX-U <sup>251)</sup> ; LD-U <sup>83)</sup>	0311 <sup>82)</sup> ; 0312 <sup>82)</sup>
0104	(24R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26, 27-hexol (Scymnol)	Sharks and rays <sup>82, 111, 112, 121, 158)</sup>	CA <sup>32)</sup>
0105	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26, 27-hexol (5 $\alpha$ -Dermophol)	Amphibians <sup>136)</sup>	0325 <sup>137)</sup>
0106	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26, 27-hexol (5 $\beta$ -Dermophol)	Amphibians <sup>136)</sup>	0326 <sup>136)</sup>

a. All natural sources refer to bile, unless otherwise referred to specific source details, which are shown by the following abbreviations: U, urine; S, serum; F, feces; L, liver; AF, amniotic fluid; GC, gastric content; M, meconium; UCB, umbilical cord blood.

Diseases are shown by the following abbreviations: CTX, cerebrotendinous xanthomatosis; HS, hyper-sitosterolemia; HSDD, 3 $\alpha$ -hydroxysteroid dehydrogenase deficiency; LD, liver diseases; ZS, Zellweger syndrome; CHO, cholestasis; RF, Refsum disease; COA, coprostanic acidemia; THD, thiolase deficiency;  $\beta$ OD,  $\beta$ -oxidation deficiency; IO, intestinal obstruction; NALD, neonatal adrenoleukodystrophy; IBDA, intrahepatic bile duct anomalies; IMA, intestinal malabsorption; SH, subdural hematoma.

b. Bile acids and bile alcohols having no trivial names are shown as their compound numbers which are given in the first column of each tables.

Abbreviations for bile acids and bile alcohols (systematic name or compound number in parentheses): CA, cholic acid (3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholan-24-oic acid); DCA, deoxycholic acid (3 $\alpha$ , 12 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid); CDCA, chenodeoxycholic acid (3 $\alpha$ , 7 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid); UDCA, ursodeoxycholic acid (3 $\alpha$ , 7 $\beta$ -dihydroxy-5 $\beta$ -cholan-24-oic acid); HDCA, hyodeoxycholic acid (3 $\alpha$ , 6 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid); LCA, lithocholic acid (3 $\alpha$ -hydroxy-5 $\beta$ -cholan-24-oic acid); 22-OH-CDCA, 22R-hydroxychenodeoxycholic acid (formerly haemulcholic acid, (22R)-3 $\alpha$ , 7 $\alpha$ , 22-trihydroxy-5 $\beta$ -cholan-24-oic acid)<sup>99, 139)</sup>; 23-OH-CDCA, 23R-hydroxychenodeoxycholic acid (formerly phocaecholic acid, (23R)-3 $\alpha$ , 7 $\alpha$ , 23-trihydroxy-5 $\beta$ -cholan-24-oic acid)<sup>208)</sup>; 6-OH-7-ODCA, 6 $\alpha$ -hydroxy-7-oxodeoxycholic acid (3 $\alpha$ , 6 $\alpha$ , 12 $\alpha$ -trihydroxy-7-oxo-5 $\beta$ -cholan-24-oic acid)<sup>235)</sup>; ACA, allocholic acid (3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\alpha$ -cholan-24-oic acid)<sup>185)</sup>; 7-EACA, 7-epiallocholic acid (3 $\alpha$ , 7 $\beta$ , 12 $\alpha$ -trihydroxy-5 $\alpha$ -cholan-24-oic acid)<sup>8)</sup>; NCA, norcholic acid (1204); NHDCA, norhyodeoxycholic acid (1213); NCDCA, norchenodeoxycholic acid (1214); NUDCA, norursodeoxycholic acid (1215); NDCA, nordeoxycholic acid (1216); NLCA, norlithocholic acid (1218); BNCA, bisnorcholic acid (1303); BNDCA, bisnordeoxycholic acid (1308); HoCA, homocholeic acid (1107); HoCDCA, homochenodeoxycholic acid (1114); CAld, cholyl aldehyde (0613); CDCAld, chenodeoxycholyl aldehyde (0620); NCAld, norcholyl aldehyde (0624); BNCAld, bisnorcholyl aldehyde (0640); CY, 5 $\alpha$ -cyprinol (0222); DECY, 27-deoxy-5 $\alpha$ -cyprinol (0323); ANSC, anhydroscymnol (24, 26-epoxy-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 27-tetrol)<sup>65)</sup>; ANCY, anhydro-5 $\alpha$ -cyprinol (26, 27-epoxy-5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol)<sup>90)</sup>; DNCT, (26, 27-dinor-5 $\alpha$ -cholest-24-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol)<sup>179)</sup>; TADNC, (3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triformoxy-25-acetoxy-26, 27-dinor-5 $\beta$ -cholestan-24-one)<sup>214)</sup>.

c. not reported.

**Table 2.** Penta-oxygenated C<sub>27</sub> bile alcohols

No.	Systematic name (Trivial name)	Natural source	Synthetic source
0201	5 $\beta$ -Cholestane-2 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-pentol (Arapaimol-A)	<i>Arapaima gigas</i> <sup>78)</sup> ; Frogs <sup>14)</sup>	—
0202	5 $\beta$ -Cholestane-3 $\alpha$ , 6 $\alpha$ , 7 $\beta$ , 25, 26-pentol ( $\omega$ -Trichechol)	Manatee <sup>173)</sup>	—
0203	5 $\beta$ -Cholestane-3 $\alpha$ , 6 $\beta$ , 7 $\alpha$ , 25, 26-pentol ( $\alpha$ -Trichechol)	Manatee <sup>173)</sup> ; Rat <sup>86)</sup>	1105 <sup>256)</sup>
0204	5 $\beta$ -Cholestane-3 $\alpha$ , 6 $\beta$ , 7 $\beta$ , 25, 26-pentol ( $\beta$ -Trichechol)	Manatee <sup>173)</sup>	—
0205	(22R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 25-pentol	CTX <sup>226)</sup> , -U <sup>226, 251)</sup>	BNCAld <sup>135)</sup>
0206	(22S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 25-pentol	—	BNCAld <sup>135)</sup>
0207	(22R, 25R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 26-pentol	—	0806 <sup>247)</sup>
0208	(22S, 25R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 26-pentol	—	0806 <sup>247)</sup>
0209	(23S)-5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol	CTX-U <sup>149)</sup>	—
0210	(23R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol	CTX-U <sup>226)</sup>	0306 <sup>141)</sup> ; 1104 <sup>103, 146)</sup>
0211	(23S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol	CTX <sup>104, 225, 226)</sup> , -U <sup>226, 251)</sup> , -F <sup>225, 226, 255)</sup>	0307 <sup>141)</sup> ; 1104 <sup>103, 146)</sup>
0212	(23R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 26-pentol	—	0306 <sup>247)</sup>
0213	(23S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 26-pentol	—	0307 <sup>247)</sup>
0214	(24R)- and (24S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25-pentols	Human <sup>172)</sup> , -S <sup>84)</sup> , -U <sup>82, 83, 174)</sup> , CTX <sup>104, 221, 225, 226)</sup> , -U <sup>226, 251)</sup> , -F <sup>221, 225, 226, 255)</sup> ; HS-F, U <sup>55)</sup> LD-U <sup>83)</sup>	0405 <sup>44, 91)</sup>
0215	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25-pentol	HSDD <sup>108)</sup>	—
0216	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol (5 $\alpha$ -Chimaerol)	White sucker <sup>13)</sup> ; Fishes <sup>15)</sup> ; Lungfish <sup>6)</sup>	—
0217	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol (5 $\beta$ -Chimaerol)	<i>Chimaera monstrosa</i> <sup>33)</sup> ; Sharks and rays <sup>32, 112, 202)</sup> ; Rat <sup>86)</sup> ; Human <sup>172)</sup> , -S <sup>84)</sup> , -U <sup>82, 83)</sup> ; CHO-U <sup>107, 120)</sup> ; LD-U <sup>83)</sup>	ANSC <sup>42)</sup>
0218	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol (5 $\alpha$ -Bufol)	Coelacanth <sup>6, 142)</sup> ; Lungfish <sup>6)</sup> ; Frogs <sup>14, 240)</sup> ; Newt <sup>98)</sup> ; Rat <sup>86)</sup>	0403 <sup>98)</sup>
0219	5 $\alpha$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol	Coelacanth <sup>142)</sup>	0404 <sup>142)</sup>
0220	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol (5 $\beta$ -Bufol)	Toads and frogs <sup>14, 97, 161, 166, 201, 240, 257)</sup> ; Rat <sup>86)</sup> ; Human <sup>172)</sup> , -S <sup>84, 85)</sup> , -U <sup>82, 83, 174, 177)</sup> ; CTX-U <sup>226)</sup> , -F <sup>52)</sup> ; CHO-U <sup>107, 120)</sup> ; HS-U, F <sup>55)</sup> ; LD-U <sup>83, 177)</sup>	HoCA <sup>146)</sup> ; 0406 <sup>91)</sup>
0221	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol	HSDD <sup>108)</sup>	—
0222	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentol (5 $\alpha$ -Cyprinol)	Carp and related fishes <sup>9, 15, 93, 94, 216)</sup> ; White sucker <sup>13)</sup> ; Coelacanth <sup>6, 142)</sup> ; Lungfishes <sup>6)</sup> ; Giant salamander <sup>5)</sup> ; Frogs <sup>14, 161, 197, 240)</sup>	—
0223	5 $\alpha$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentol (Latimerol)	Coelacanth <sup>6, 10, 142)</sup>	—
0224	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentol (5 $\beta$ -Cyprinol)	Fishes <sup>15, 43, 76, 95)</sup> ; Toads and frogs <sup>14, 131, 161, 240)</sup> ; Human <sup>172)</sup> , -U <sup>174)</sup> ; CHO-U <sup>106, 107)</sup>	CA <sup>76, 92)</sup>

For abbreviations, see Table 1.

**Table 3.** Tetra-oxygenated C<sub>27</sub> bile alcohols


No.	Systematic name (Trivial name)	Natural source	Synthetic source
0301	5 $\beta$ -Cholestane-3 $\alpha$ , 6 $\beta$ , 7 $\alpha$ , 26-tetrol	Manatee <sup>173)</sup>	—
0302	(22R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22-tetrol	—	BNCAld <sup>165)</sup>
0303	(22S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22-tetrol	—	BNCAld <sup>165)</sup>
0304	(23R)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	CTX <sup>104, 226)</sup> , -U <sup>226, 251)</sup> , -F <sup>140, 226, 255)</sup>	0307 <sup>141)</sup> ; 0308 <sup>165)</sup>
0305	(23S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	—	0308 <sup>165)</sup>
0306	(23R)-5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	—	NCAld <sup>141)</sup>
0307	(23S)-5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	—	NCAld <sup>141)</sup>
0308	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-23-one	—	NCA <sup>165)</sup>
0309	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	Fishes <sup>15)</sup> ; Lungfish <sup>6)</sup> ; Rabbit <sup>193)</sup> ; Human <sup>172)</sup> ; CTX <sup>226)</sup>	—
0310	(24R)- and (24S)-5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrols	Rabbit <sup>193)</sup> ; Human <sup>172)</sup> ; CTX <sup>104, 226)</sup> , -U <sup>226)</sup> , -F <sup>226, 255)</sup> , HS-U, F <sup>55)</sup>	0313 <sup>180, 227)</sup> ; 0809 <sup>241)</sup> ; 0405 <sup>48)</sup>
0311	(24R)-5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	—	CAld <sup>82)</sup>
0312	(24S)-5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	—	CAld <sup>82)</sup>
0313	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-24-one	—	CA <sup>227)</sup>
0314	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	HSDD <sup>108)</sup>	—
0315	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	CTX-U, F <sup>226)</sup>	0403 <sup>226)</sup>
0316	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	Alligator <sup>237)</sup> ; Rabbit <sup>193)</sup> ; Human <sup>172)</sup> , -S <sup>157)</sup> , -L <sup>200)</sup> ; CTX <sup>104, 200, 221, 226)</sup> , -S <sup>157)</sup> , -U <sup>226, 251)</sup> , -F <sup>221, 226, 255)</sup> , -L <sup>200)</sup> ; HS-U, F <sup>55)</sup>	HoCA <sup>44, 50, 116, 146, 207)</sup>
0317	5 $\beta$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	—	0319 <sup>53)</sup>
0318	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\beta$ , 12 $\alpha$ , 25-tetrol	—	1110 <sup>226)</sup>
0319	7 $\alpha$ , 12 $\alpha$ , 25-Trihydroxy-5 $\beta$ -cholestan-3-one	—	0316 <sup>116)</sup>
0320	3 $\alpha$ , 12 $\alpha$ , 25-Trihydroxy-5 $\beta$ -cholestan-7-one	CTX <sup>226)</sup> , -F <sup>226)</sup>	0316 <sup>226)</sup>
0321	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	HSDD <sup>108)</sup>	—
0322	7 $\alpha$ , 12 $\alpha$ , 25-Trihydroxycholest-4-en-3-one	—	0319 <sup>116)</sup>
0323	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol (27-Deoxy-5 $\alpha$ -cyprinol)	Carp <sup>96)</sup> ; Fishes <sup>15)</sup> ; Lungfishes <sup>6)</sup> ; Toads <sup>97, 257)</sup> ; Frogs <sup>14)</sup> ; Alligator <sup>237)</sup> ; Rat <sup>86)</sup>	ANCY <sup>90)</sup>
0324	(25R)- and (25S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrols	Toads and frogs <sup>14, 97, 240, 257)</sup> ; Rat <sup>86)</sup> ; Human <sup>172)</sup> ; CHO-U <sup>106, 107)</sup>	0902 <sup>13, 51, 63, 130)</sup> ; 0406 <sup>48)</sup>
0325	5 $\alpha$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 27-tetrol	—	0909 <sup>137)</sup>
0326	5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 27-tetrol	—	0910 <sup>136)</sup>
0327	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-26-al	—	0324 <sup>51)</sup> ; CAld <sup>203)</sup>
0328	7 $\alpha$ , 12 $\alpha$ , 26-Trihydroxy-5 $\beta$ -cholestan-3-one	—	0324 <sup>51)</sup>
0329	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-5 $\beta$ -cholestan-26-al	—	0324 <sup>51)</sup>
0330	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol	HSDD <sup>108)</sup>	—
0331	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 16 $\alpha$ , 26-tetrol (3-Epimyxinol)	Hagfish <sup>239)</sup>	—
0332	5 $\alpha$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 16 $\alpha$ , 26-tetrol (Myxinol)	Hagfishes <sup>11, 73, 239)</sup>	—
0333	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 24, 25-tetrol	—	0414 <sup>20, 164)</sup>
0334	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 24, 26-tetrol	Human <sup>245)</sup>	0917 <sup>245)</sup>
0335	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 25, 26-tetrol	Manatee <sup>173)</sup> ; Human <sup>245)</sup>	0414 <sup>164)</sup>
0336	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 25, 26-tetrol	HSDD <sup>108)</sup>	—
0337	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 26, 27-tetrol	—	CY <sup>161)</sup>
0338	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 26, 27-tetrol	Human <sup>245)</sup>	1005 <sup>245)</sup>

For abbreviations, see Table 1.

**Table 4.** Tri-oxygenated C<sub>27</sub> bile alcohols

No.	Systematic name (Trivial name)	Natural source	Synthetic source
0401	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0403 <sup>102)</sup>
0402	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	Human-L <sup>200)</sup> ; CTX-F <sup>200, 226)</sup> , -L <sup>200)</sup>	CA <sup>26, 127)</sup> ; 0313 <sup>219, 227)</sup>
0403	5 $\alpha$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	DECY <sup>98)</sup>
0404	5 $\alpha$ -Cholest-25-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0403 <sup>142)</sup>
0405	5 $\beta$ -Cholest-24-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0316 <sup>44, 48, 91)</sup>
0406	5 $\beta$ -Cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	CTX <sup>200)</sup>	0316 <sup>44, 48, 91)</sup>
0407	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-5 $\alpha$ -cholestan-3-one	—	0401 <sup>102)</sup>
0408	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-3-one	—	0402 <sup>27)</sup>
0409	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-7-one	—	0402 <sup>63)</sup>
0410	Cholest-4-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0411 <sup>102)</sup>
0411	7 $\alpha$ , 12 $\alpha$ -Dihydroxycholest-4-en-3-one	—	0408 <sup>27, 102)</sup>
0412	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 24-triol	Human <sup>172)</sup>	0414 <sup>47)</sup>
0413	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 25-triol	—	1113 <sup>87)</sup>
0414	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 25-triol	Human <sup>172)</sup>	HoCDCA <sup>40, 116)</sup>
0415	5 $\beta$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 25-triol	—	0414 <sup>53)</sup>
0416	7 $\alpha$ , 25-Dihydroxy-5 $\beta$ -cholestan-3-one	—	0414 <sup>116)</sup>
0417	5 $\alpha$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 26-triol (3-Epi-16-deoxymyxinol)	Hagfish <sup>239)</sup>	DECY <sup>239)</sup>
0418	5 $\beta$ -Cholestane-3 $\alpha$ , 7 $\alpha$ , 26-triol	Human <sup>172)</sup>	0414 <sup>47)</sup>
0419	5 $\alpha$ -Cholestane-3 $\beta$ , 7 $\alpha$ , 26-triol (16-Deoxymyxinol)	Hagfish <sup>12, 239)</sup>	Kryptogenin <sup>196)</sup>
0420	Cholest-5-ene-3 $\beta$ , 7 $\alpha$ , 26-triol	HSDD <sup>108)</sup>	—
0421	7 $\alpha$ , 25-Dihydroxycholest-4-en-3-one	—	0416 <sup>116)</sup>

For abbreviations, see Table 1.



**Fig. 1.** Cholestane skeleton.

Bile alcohols with a cholestane skeleton are numbered as in Fig. 1. If one of the methyl groups attached to C-25 is substituted, it is

assigned the lower number, C-26, as recommended by IUPAC-IUB Joint Commission on Biochemical Nomenclature<sup>191)</sup>. Hence, what is termed, mistakenly, as “5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,27-tetrol” should be correctly called (25R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol (III).

The occurrence of bile alcohols in nature was first demonstrated in 1898 by Hammarsten who found that the bile of the northern shark *Scymnus borealis* contains the sulfate ester of a neutral steroid named scymnol as its major constituent<sup>65)</sup>. The structure of scymnol eluded investigators for many years, and was verified by partial synthesis in 1962<sup>32)</sup>. The configuration of 24-hydroxyl group was finally determined in 1991 by means of X-ray diffraction analyses<sup>112)</sup>. Scymnol sulfate has been found in all elasmobranchii (sharks and rays) as their major bile salt, but has not been located in other natural sources<sup>75)</sup>.

**Table 5.** C<sub>26</sub> Bile alcohols

No.	Systematic name (Trivial name)	Natural source	Synthetic source
0501	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol	—	0509 <sup>45)</sup>
0502	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	—	0509 <sup>49)</sup>
0503	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	Rabbit <sup>193)</sup> ; Human <sup>172)</sup> ; CHO <sup>133)</sup>	CA <sup>45)</sup>
0504	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol	—	0510 <sup>49)</sup>
0505	(22R)-24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 22, 25-tetrol	—	22-OH-CDCA <sup>99)</sup>
0506	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 23, 25-tetrol	—	0513 <sup>163)</sup>
0507	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 25, 26-tetrol	—	0514 <sup>163)</sup>
0508	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0503 <sup>45, 49)</sup>
0509	24-Nor-5 $\beta$ -cholest-23-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0503 <sup>45, 49)</sup>
0510	24-Nor-5 $\beta$ -cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0503 <sup>45, 49)</sup>
0511	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 25-triol	—	CDCA <sup>163)</sup>
0512	24-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\beta$ , 25-triol	—	UDCA <sup>182)</sup>
0513	24-Nor-5 $\beta$ -cholest-23-ene-3 $\alpha$ , 7 $\alpha$ -diol	—	0511 <sup>163)</sup>
0514	24-Nor-5 $\beta$ -cholest-25-ene-3 $\alpha$ , 7 $\alpha$ -diol	—	0511 <sup>163)</sup>
0515	27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25, 26-hexol	Human <sup>172)</sup> , -S <sup>84)</sup> , -U <sup>82, 83)</sup> ; CHO-U <sup>120)</sup> ; LD-U <sup>83)</sup>	0523 <sup>172)</sup>
0516	27-Norcholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25-pentol	Rat <sup>86)</sup> ; Human <sup>172)</sup> , -S <sup>84, 85)</sup> , -U <sup>82, 83, 84, 119, 177)</sup> ; CTX-U <sup>226)</sup> ; ZS <sup>57)</sup> ; CHO-U <sup>107)</sup> ; LD-U <sup>83, 177)</sup> ; HS-U, F <sup>55)</sup>	CA <sup>55)</sup> ; 0529 <sup>174)</sup>
0517	27-Norcholest-5-ene-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25-pentol	HSDD <sup>108)</sup>	—
0518	27-Nor-5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol (5 $\alpha$ -Ranol)	Frogs <sup>14, 69, 72, 197, 240)</sup>	—
0519	(24R)-27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol (5 $\beta$ -Ranol)	Frogs <sup>14, 132, 161, 197, 240)</sup>	1101 <sup>132, 167)</sup> ; 0523 <sup>145)</sup>
0520	(24S)-27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol (24-Epi-5 $\beta$ -ranol)	—	1101 <sup>167)</sup>
0521	(24R)- and (24S)-27-Nor-5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrols (24-Epi-26-deoxy-5 $\alpha$ -ranol and 26-Deoxy-5 $\alpha$ -ranol)	Frogs <sup>14, 197, 240)</sup>	0525 <sup>197)</sup>
0522	(24R)- and (24S)-27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrols (24-Epi-26-deoxy-5 $\beta$ -ranol and 26-Deoxy-5 $\beta$ -ranol)	Frogs <sup>14, 197, 240)</sup>	0526 <sup>197)</sup> ; 0523 <sup>145)</sup>
0523	(24R)- and (24S)-27-Nor-5 $\beta$ -cholest-25-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrols	Human <sup>172)</sup>	CAld <sup>145, 172)</sup>
0524	27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol	—	1102 <sup>130)</sup>
0525	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-27-nor-5 $\alpha$ -cholestan-24-one	Bullfrog <sup>198)</sup>	ACA <sup>197)</sup>
0526	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-27-nor-5 $\beta$ -cholestan-24-one	Bullfrog <sup>198)</sup> ; Human <sup>172)</sup> ; THD <sup>39)</sup> ; $\beta$ OD <sup>39)</sup>	CA <sup>197)</sup>
0527	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-27-nor-5 $\beta$ -cholestan-25-one	—	HoCA <sup>201)</sup>
0528	27-Nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0526 <sup>126)</sup>
0529	27-Nor-5 $\beta$ -cholest-24-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	CAld <sup>174)</sup>

For abbreviations, see Table 1.

**Table 6.** C<sub>25</sub>, C<sub>24</sub>, C<sub>23</sub>, and C<sub>22</sub> Bile alcohols

No.	Systematic name (Trivial name)	Natural source	Synthetic source
0601	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25-pentol	CHO <sup>133)</sup>	TADNC <sup>254)</sup>
0602	26, 27-Dinor-5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	Frogs <sup>14)</sup>	—
0603	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol	Frogs <sup>14)</sup>	0604 <sup>134)</sup>
0604	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-24-one	CHO <sup>133)</sup>	CA <sup>125)</sup>
0605	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol	—	HoCA <sup>130)</sup>
0606	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 24, 25-tetrol	—	CDCA <sup>88)</sup>
0607	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	0604 <sup>125)</sup>
0608	26, 27-Dinor-5 $\beta$ -cholestane-3 $\alpha$ , 24, 25-triol	—	LCA <sup>189)</sup>
0609	3 $\alpha$ , 6 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-5 $\beta$ -cholan-24-al	—	6-OH-7-ODCA <sup>248)</sup>
0610	5 $\alpha$ -Cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol (5 $\alpha$ -Petromyzonol)	Lamprey <sup>77)</sup> ; Lungfishes <sup>6)</sup>	ACA <sup>77)</sup>
0611	5 $\beta$ -Cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-tetrol (5 $\beta$ -Petromyzonol)	Lungfish <sup>6)</sup> ; Human <sup>172)</sup>	CA <sup>150, 166, 250)</sup>
0612	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholan-24-al	—	DNCT <sup>198)</sup>
0613	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholan-24-al (Cholyl aldehyde)	—	0601 <sup>254)</sup> ; CA <sup>63, 241)</sup>
0614	(23R)-5 $\beta$ -Cholane-3 $\alpha$ , 7 $\alpha$ , 23, 24-tetrol	Human <sup>172)</sup>	23-OH-CDCA <sup>172)</sup>
0615	5 $\beta$ -Cholane-3 $\alpha$ , 6 $\alpha$ , 24-triol	—	HDCA <sup>150)</sup>
0616	5 $\beta$ -Cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	CA <sup>125)</sup>
0617	5 $\beta$ -Cholane-3 $\alpha$ , 7 $\alpha$ , 24-triol	—	CDCA <sup>148)</sup>
0618	5 $\beta$ -Cholane-3 $\alpha$ , 7 $\beta$ , 24-triol	—	UDCA <sup>148)</sup>
0619	5 $\beta$ -Cholane-3 $\alpha$ , 12 $\alpha$ , 24-triol	—	DCA <sup>150, 250)</sup>
0620	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\beta$ -cholan-24-al (Chenodeoxycholyl aldehyde)	—	0606 <sup>88)</sup>
0621	5 $\beta$ -Cholane-3 $\alpha$ , 24-diol	—	LCA <sup>150, 250)</sup>
0622	3 $\alpha$ -Hydroxy-5 $\beta$ -cholan-24-al (Lithocholyl aldehyde)	—	0608 <sup>189)</sup>
0623	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 23-pentol	—	0634 <sup>135)</sup>
0624	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\beta$ -cholan-23-al (Norcholyl aldehyde)	—	NCA <sup>141)</sup> ; CA <sup>223)</sup>
0625	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol	—	NCA <sup>150)</sup>
0626	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\alpha$ , 22, 23-tetrol	—	0636 <sup>139)</sup>
0627	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\beta$ , 22, 23-tetrol	—	0637 <sup>143)</sup>
0628	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 12 $\alpha$ , 22, 23-tetrol	—	0638 <sup>143)</sup>
0629	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 6 $\alpha$ , 23-triol	—	NHDCA <sup>150)</sup>
0630	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	NCA <sup>153)</sup>
0631	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\alpha$ , 23-triol	—	NCDCA <sup>150)</sup>
0632	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 7 $\beta$ , 23-triol	—	NUDCA <sup>150)</sup>
0633	24-Nor-5 $\beta$ -cholane-3 $\alpha$ , 12 $\alpha$ , 23-triol	—	NDCA <sup>150)</sup>
0634	24-Nor-5 $\beta$ -chol-22-ene-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol	—	CA <sup>36, 135)</sup>
0635	24-Nor-5 $\beta$ -chol-22-ene-3 $\alpha$ , 6 $\alpha$ -diol	—	HDCA <sup>36)</sup>
0636	24-Nor-5 $\beta$ -chol-22-ene-3 $\alpha$ , 7 $\alpha$ -diol	—	CDCA <sup>36, 139)</sup>
0637	24-Nor-5 $\beta$ -chol-22-ene-3 $\alpha$ , 7 $\beta$ -diol	—	UDCA <sup>36)</sup>
0638	24-Nor-5 $\beta$ -chol-22-ene-3 $\alpha$ , 12 $\alpha$ -diol	—	DCA <sup>36)</sup>
0639	3 $\alpha$ -Hydroxy-24-nor-5 $\beta$ -cholan-23-al	—	LCA <sup>212, 253)</sup>
0640	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-al (Bisnorcholyl aldehyde)	—	0623 <sup>135)</sup>
0641	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-al (Bisnorchenodeoxycholyl aldehyde)	—	0626 <sup>139)</sup>
0642	3 $\alpha$ , 7 $\beta$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-al (Bisnorursodeoxycholyl aldehyde)	—	0627 <sup>143)</sup>
0643	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-al (Bisnordeoxycholyl aldehyde)	—	0628 <sup>143)</sup>
0644	3 $\alpha$ -Hydroxy-23, 24-dinor-5 $\beta$ -cholan-22-al	—	LCA <sup>253)</sup>

For abbreviations, see Table 1.




Fig. 2. Postulated structural relationship between 5 $\beta$ -chimaerol (I) and scymnol (II).





Fig. 3. Postulated structural relationship between (25R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol (III) and 5 $\beta$ -bufol (IV).

5 $\beta$ -Chimaerol sulfate is the chief bile salt of *Chimaera monstrosa*<sup>33)</sup> and a minor companion of scymnol sulfate in the bile of elasmobranchii<sup>112, 202)</sup>. 5 $\beta$ -Chimaerol or its isomer with respect to C-24 and/or C-25 position has also been found in human bile<sup>172)</sup> and urine<sup>82, 83)</sup>. The stereochemistry of the side chain of 5 $\beta$ -chimaerol remains unresolved, but the configuration at C-25 has been suggested as S on the basis of the data from molecular rotation contribution studies<sup>33)</sup>. The structural relationship between scymnol and 5 $\beta$ -chimaerol (the latter is the 27-deoxy derivative of the former) as well as the co-existence of both bile alcohols in elasmobranchii bile and probably also in *Chimaera monstrosa* bile<sup>74)</sup> suggests that 5 $\beta$ -chimaerol (I) is the biosynthetic precursor of scymnol (II); hence the configuration at C-24 of 5 $\beta$ -chimaerol (I) should be the same, namely R, as that at C-24 of scymnol (II) (Fig. 2).

A principal bile alcohol of the white sucker *Catostomus commersoni* has the structure 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 26-pentol, whose configuration at C-24 and C-25 was assumed to be the same as those of 5 $\beta$ -chimaerol, and named 5 $\alpha$ -chimaerol<sup>13)</sup>.

A number of 26-hydroxylated and 25, 26-dihydroxylated cholestane derivatives have been found not only in primitive vertebrates but also in mammals including humans. However, the configuration at C-25 of most of these bile alcohols is still undetermined. In biosynthetic experiments using radioactive mevalonate of 5 $\beta$ -bufol in the toad *Bufo vulgaris formosus*, it was shown that the terminal hydroxyl-bearing carbon atom (C-26) of 5 $\beta$ -bufol is derived from C-3' of mevalonate<sup>162)</sup>. This indicates that in the biosynthesis of 5 $\beta$ -bufol the hydroxylation at the end methyl group of the cholesterol side chain is stereospecific, and the configuration at C-25 of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol, the direct precursor of 5 $\beta$ -bufol, is R. (25R)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol (III) has been recognized as an intermediate in the biosynthetic sequence between cholesterol and cholic acid in mammals<sup>28)</sup>. Thus, until the formation of (25R)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol (III), the pathway for the synthesis of 5 $\beta$ -bufol (IV) in the toad is the same as that for the synthesis of cholic acid in mammals. If 25-hydroxylation of (25R)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol (III) takes place by the direct dis-





**Fig. 4.** Structural relationship of (23S)-5β-cholest-25-ene-3α,7α,12α,23-tetrol (V), and (23R)-5β-cholestane-3α,7α,12α,23-tetrol (VI) and (23S)-5β-cholestane-3α,7α,12α,23,25-pentol (VII).

placement mechanism with retention of the configuration, as with hydroxylation of steroids by mixed function oxidases, the configuration at C-25 of 5β-bufol (IV) could be assigned as S (Fig. 3).


Cerebrotendinous xanthomatosis (CTX) is a rare inherited disease caused by an inborn error of cholesterol catabolism and is characterized by accumulation of bile alcohols<sup>221</sup>. The absolute configuration at C-23 of 5β-cholestane-3α,7α,12α,23-tetrol (VI), one of the bile alcohols isolated from the bile, urine, and feces of patients with CTX, was determined as R by X-ray crystallography<sup>140</sup>. The 23S-epimer has not yet been detected in nature.

One of two stereoisomers at C-23 of 5β-cholestane-3α,7α,12α,23,25-pentol is a chief bile alcohol of the urine from CTX patients<sup>226, 251</sup>, and a second or a third bile alcohol of the bile and feces<sup>104, 225, 226</sup>. The configuration at C-23 of the 23,25-pentol (VII) was tentatively assigned as S [the same as that at C-23 of the naturally occurring (23R)-5β-cholestane-3α,7α,12α,23-tetrol (VI)] on the basis of optical rotation differences<sup>103</sup>. However, the opposite configuration at C-23 of the 23,25-pentol (VII) was assigned by a circular dichroism study<sup>46</sup>. Defi-

nite assignment of the 23S configuration of 5β-cholestane-3α,7α,12α,23,25-pentol (VII) was made by the conversion of a key intermediate, (23S)-5β-cholest-25-ene-3α,7α,12α,23-tetrol (V), to either the 23,25-pentol (VII) or the bile alcohol of known absolute configuration, (23R)-5β-cholestane-3α,7α,12α,23-tetrol (VI) (Fig. 4)<sup>141</sup>. (23R)-5β-Cholestane-3α,7α,12α,23,25-pentol was detected only in the urine of a CTX patient in a trace amount<sup>226</sup>.

Recently, a bile alcohol isolated from the urine of CTX patients was identified as 5α-cholestane-3α,7α,12α,23,25-pentol<sup>149</sup>. The configuration at C-23 of the 5α-bile alcohol was deduced as S by the comparison of its <sup>13</sup>C-nuclear magnetic resonance spectrum with those of (23R)- and (23S)-5β-cholestane-3α,7α,12α,23,25-pentols.

5β-Ranol, a principal bile alcohol of the bullfrog, *Rana catesbeiana*, was identified as (24R)-27-nor-5β-cholestane-3α,7α,12α,24,26-pentol (XI)<sup>145, 167</sup>. However, the 24S-epimer (XII) of 5β-ranol (XI) could not be detected in the bullfrog bile, though both stereoisomers at C-24 of 27-nor-5β-cholestane-3α,7α,12α,24-tetrol, 26-deoxy-5β-ranol (IX) and 24-epi-26-deoxy-5β-ranol (X) were found in this bile<sup>197</sup>. The bile alcohol pattern of the bullfrog bile is consistent with the results from the



**Fig. 5.** Biosynthetic route of  $C_{26}$  bile alcohols in bullfrog. VIII,  $3\alpha,7\alpha,12\alpha$ -trihydroxy-27-nor- $5\beta$ -cholestan-24-one; IX, 26-deoxy- $5\beta$ -ranol [(24S)-27-nor- $5\beta$ -cholestane- $3\alpha,7\alpha,12\alpha,24$ -tetrol]; X, 24-epi-26-deoxy- $5\beta$ -ranol [(24R)-27-nor- $5\beta$ -cholestane- $3\alpha,7\alpha,12\alpha,24$ -tetrol]; XI,  $5\beta$ -ranol [(24R)-27-nor- $5\beta$ -cholestane- $3\alpha,7\alpha,12\alpha,24,26$ -pentol]; XII, 24-epi- $5\beta$ -ranol [(24S)-27-nor- $5\beta$ -cholestane- $3\alpha,7\alpha,12\alpha,24,26$ -pentol].

biosynthetic experiments of  $5\beta$ -ranol (XI), which showed that in the bullfrog  $3\alpha,7\alpha,12\alpha$ -trihydroxy-27-nor- $5\beta$ -cholestan-24-one (VIII) formed from cholesterol is converted into both 26-deoxy- $5\beta$ -ranol (IX) and 24-epi-26-deoxy- $5\beta$ -ranol (X), and only 26-deoxy- $5\beta$ -ranol (IX) can be hydroxylated at C-26 to give  $5\beta$ -ranol (XI), but not 24-epi-26-deoxy- $5\beta$ -ranol (X) to 24-epi- $5\beta$ -ranol (XII) (Fig. 5)<sup>199</sup>.

#### Higher Bile Acids

Higher bile acids are here defined as higher homologs with an extended side chain of  $C_{24}$  bile

acids.

Tables 7–11 list all the naturally occurring higher bile acids of established structure and most chemically derived higher bile acids. Steroidal acids found in natural sources other than vertebrates, e.g. plants and invertebrates, chemically synthesized bile acids carrying no hydroxyl group, and esterified derivatives, are not included in the tables.

Higher bile acids are usually designated their systematic names, because they have no trivial names except with arapaimic acid and varanic acid.

**Table 7.** C<sub>29</sub> and C<sub>28</sub> Bile acids

No.	Systematic name	Natural source	Synthetic source
0701	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-Tetrahydroxy-24-ethyl-5 $\beta$ -cholestan-26-oic acid	—	0526 <sup>188)</sup>
0702	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-ethyl-5 $\beta$ -cholestan-26-oic acid	—	0701 <sup>188)</sup>
0703	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-carboxymethyl-5 $\beta$ -cholestan-26-oic acid	—	NCA <sup>114)</sup>
0704	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-27-carboxymethyl-5 $\beta$ -cholestan-26-oic acid	ZS <sup>39, 59, 123, 205)</sup> , -S <sup>38, 39, 59, 122, 123, 205, 220)</sup> , -U <sup>39, 59, 205)</sup> ; RF-S <sup>38)</sup> ; COA <sup>205)</sup> , -S <sup>114, 205)</sup> , -U <sup>115, 205)</sup>	CAId <sup>206)</sup>
0705	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-ethyl-5 $\beta$ -cholestane-26, 27-dioic acid	—	NCA <sup>114)</sup>
0706	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-24-ethyl-5 $\beta$ -cholestan-26-oic acid	Sitosterol-fed monkey-F <sup>159)</sup>	—
0707	3 $\alpha$ -Hydroxy-24-ethyl-5 $\beta$ -cholestan-26-oic acid	Sitosterol-fed monkey-F <sup>159)</sup>	—
0708	3 $\beta$ -Hydroxy-24-ethylcholest-5-en-26-oic acid	Sitosterol-fed monkey-F <sup>159)</sup>	—
0709	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-Tetrahydroxy-24-methyl-5 $\beta$ -cholestan-26-oic acid	Toad <sup>242)</sup>	0604 <sup>89)</sup>
0710	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-methyl-5 $\beta$ -cholestan-26-oic acid	Bullfrog <sup>198)</sup>	0711 <sup>89)</sup>
0711	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-methyl-5 $\beta$ -cholest-23-en-26-oic acid	—	0709 <sup>89)</sup>
0712	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestane-24-carboxylic acid	—	0313 <sup>100)</sup>
0713	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholest-22-ene-24-carboxylic acid	Toad <sup>242)</sup>	—
0714	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholest-22-ene-24-carboxylic acid	Toad <sup>228, 242)</sup>	—
0715	(25R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestane-26-carboxylic acid	—	CA <sup>31)</sup>
0716	(25S)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestane-26-carboxylic acid	—	CA <sup>31)</sup>

For abbreviations, see Table 1.

**Table 8.** Tetra-oxygenated C<sub>27</sub> bile acids

No.	Systematic name (Trivial name)	Natural source	Synthetic source
0801	1 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147)</sup> ; ZS-U <sup>220, 246)</sup>	—
0802	2 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid (Arapaimic acid)	<i>Arapaima gigas</i> <sup>78)</sup>	—
0803	3 $\alpha$ , 6 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	ZS-S <sup>122)</sup> , -U <sup>246, 248)</sup>	0804 <sup>248)</sup>
0804	3 $\alpha$ , 6 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-5 $\beta$ -cholest-24-en-26-oic acid	—	0609 <sup>248)</sup>
0805	(22R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22-Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	ZS-U <sup>246, 247)</sup>	—
0806	(22S, 25R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22-Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	Turtles <sup>4, 62, 79, 252)</sup>	—
0807	(23R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	ZS-U <sup>246, 247)</sup>	—
0808	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-Tetrahydroxy-5 $\alpha$ -cholestan-26-oic acid	Bullfrog <sup>198)</sup>	0612 <sup>198)</sup>
0809	(24R, 25R)-, (24R, 25S)-, (24S, 25R)-, and (24S, 25S)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-Tetrahydroxy-5 $\beta$ -cholestan-26-oic acids (Varanic acid)	Toad <sup>242)</sup> ; Frogs <sup>161, 198, 243)</sup> ; Alligator <sup>147)</sup> ; Lizards <sup>1, 69)</sup> ; Human <sup>182)</sup> ; ZS <sup>39, 205)</sup> , -S <sup>38, 39, 122, 123, 220)</sup> , -U <sup>68, 123, 175, 181, 220, 246)</sup> ; COA <sup>205)</sup> ; THD <sup>39)</sup> , -S <sup>39)</sup> ; $\beta$ OD <sup>39)</sup> , -S <sup>39)</sup>	CAld <sup>23, 109, 152, 241)</sup>
0810	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-Tetrahydroxy-5 $\beta$ -cholestan-26-oic acid	ZS <sup>39)</sup> , -S <sup>38, 39)</sup> , -U <sup>175, 220)</sup> ; RF-U <sup>175)</sup> ; IO-GC <sup>37)</sup> ; THD <sup>39)</sup> , -S <sup>39)</sup> ; $\beta$ OD <sup>39)</sup> , -S <sup>39)</sup>	CA <sup>41)</sup>
0811	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-Tetrahydroxy-5 $\alpha$ -cholestan-27-oic acid	Bullfrog <sup>198)</sup>	0909 <sup>198)</sup>
0812	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-Tetrahydroxy-5 $\beta$ -cholestan-27-oic acid	Toad and frogs <sup>198, 240, 257)</sup> ; Alligator <sup>147)</sup> ; Human <sup>182)</sup> ; ZS <sup>39)</sup> , -S <sup>38, 39)</sup> , -U <sup>175, 246)</sup> ; RF-S <sup>38)</sup> , -U <sup>175)</sup> ; THD <sup>39)</sup> , -S <sup>39)</sup> ; $\beta$ OD <sup>39)</sup> , -S <sup>39)</sup>	0910 <sup>240)</sup>
0813	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-Tetrahydroxy-5 $\beta$ -cholest-23-en-27-oic acid	Toad <sup>257)</sup>	—

For abbreviations, see Table 1.

**Table 9.** Tri-oxygenated C<sub>27</sub> bile acids

No.	Systematic name	Natural source	Synthetic source
0901	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholestan-26-oic acid	Coelacanth <sup>142)</sup> ; Toads and frogs <sup>161, 198, 240, 242, 257)</sup> ; Alligator <sup>147)</sup> ; Iguana <sup>204)</sup> ; Turtle <sup>*</sup>	DECY <sup>117)</sup>
0902	(25R)- and (25S)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-26-oic acids	Toads and frogs <sup>14, 154, 161, 171, 178, 198, 240, 242, 243, 257)</sup> ; Alligator <sup>22, 25, 70, 147)</sup> ; -F <sup>238)</sup> ; Crocodile <sup>70, 184)</sup> ; Lizard <sup>1)</sup> ; Turtle <sup>*</sup> ; Kite <sup>160)</sup> ; Baboon <sup>222)</sup> ; Human <sup>24, 35, 182)</sup> ; ZS <sup>39, 59, 123, 187, 205)</sup> ; -S <sup>38, 39, 59, 64, 122, 123, 187, 205, 220, 249)</sup> ; -U <sup>68, 123, 181, 205, 220, 246)</sup> ; -F <sup>205)</sup> ; -AF <sup>231)</sup> ; RF-S <sup>38, 209)</sup> ; THD <sup>39)</sup> ; -S <sup>39)</sup> ; NALD-AF <sup>231)</sup> ; IBDA <sup>58, 67)</sup> ; -S, -U, -F <sup>67)</sup> ; COA <sup>205)</sup> ; -S, -U, -F <sup>205)</sup> ; $\beta$ OD <sup>39)</sup> ; -S <sup>39)</sup> ; IO-GC <sup>37)</sup>	NCA <sup>155)</sup> ; CA <sup>34)</sup> ; HoCA <sup>21, 22)</sup> ; 0908 <sup>63)</sup> ; 0715 <sup>31)</sup> ; 0716 <sup>31)</sup>
0903	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholestan-26-oic acid	Coelacanth <sup>142)</sup>	0911 <sup>142)</sup>
0904	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator-F <sup>238)</sup>	—
0905	3 $\alpha$ , 7 $\beta$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147)</sup>	0914 <sup>147)</sup>
0906	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholest-23-en-26-oic acid	Toads <sup>242, 257)</sup>	—
0907	(25R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholest-23-en-26-oic acid	Toads <sup>80, 81, 242, 257)</sup> ; Lizard <sup>1)</sup> ; THD <sup>39)</sup>	—
0908	(24E)- and (24Z)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholest-24-en-26-oic acids	Lizard <sup>1)</sup> ; Human <sup>182)</sup> ; THD <sup>39)</sup> ; -S <sup>39)</sup>	CAld <sup>63, 110, 241)</sup>
0909	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\alpha$ -cholestane-26, 27-dioic acid	—	CY <sup>137, 198)</sup>
0910	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-5 $\beta$ -cholestane-26, 27-dioic acid	—	CA <sup>136, 240)</sup>
0911	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-5 $\alpha$ -cholestan-26-oic acid	Alligator <sup>237)</sup>	DECY <sup>142)</sup>
0912	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147, 237)</sup>	0902 <sup>147)</sup>
0913	7 $\beta$ , 12 $\alpha$ -Dihydroxy-3-oxo-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147)</sup>	—
0914	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-7-oxo-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147, 237)</sup>	0902 <sup>63, 147)</sup>
0915	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-12-oxo-5 $\alpha$ -cholestan-26-oic acid	—	0901 <sup>117)</sup>
0916	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxycholest-5-en-26-oic acid	HSDD <sup>108)</sup>	—
0917	3 $\alpha$ , 7 $\alpha$ , 24-Trihydroxy-5 $\beta$ -cholestan-26-oic acid	Lizard <sup>1)</sup> ; ZS-S <sup>122, 123)</sup> ; -U <sup>123)</sup>	CDCAld <sup>245)</sup>
0918	3 $\alpha$ , 12 $\alpha$ , 22-Trihydroxy-5 $\beta$ -cholestan-26-oic acid	Turtle <sup>79)</sup>	0806 <sup>*</sup>

\* Our unpublished observation. For abbreviations, see in Table 1.

**Table 10.** Di- and mono-oxygenated C<sub>27</sub> bile acids

No.	Systematic name	Natural source	Synthetic source
1001	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholestan-26-oic acid	—	0915 <sup>117)</sup>
1002	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>56, 147)</sup> , -F <sup>238)</sup> ; Kite <sup>160)</sup> ; Human <sup>66)</sup> ; ZS <sup>58, 59, 123, 187)</sup> , -S <sup>38,</sup> 59, 122, 123, 187, 205, 220, 249), -U <sup>59, 68,</sup> 123, 181, 205, 246), -F <sup>205)</sup> , -AF <sup>231)</sup> ; NALD-AF <sup>231)</sup> ; RF-S <sup>38)</sup> ; COA <sup>205)</sup> , -S, -U, -F <sup>205)</sup>	CDCA <sup>34, 56, 66,</sup> 138); HoCDCA <sup>21)</sup> ; 0902 <sup>25)</sup> ; 1004 <sup>88)</sup>
1003	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\beta$ -cholest-23-en-26-oic acid	Lizard <sup>1)</sup>	—
1004	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\beta$ -cholest-24-en-26-oic acid	Lizard <sup>1)</sup>	CDCA <sup>88, 110)</sup>
1005	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-5 $\beta$ -cholestane-26, 27-dioic acid	—	CDCA <sup>245)</sup>
1006	3 $\beta$ , 7 $\alpha$ -Dihydroxy-5 $\alpha$ -cholestan-26-oic acid	—	Kryptogenin <sup>192)</sup>
1007	7 $\alpha$ -Hydroxy-3-oxo-5 $\alpha$ -cholestan-26-oic acid	—	Kryptogenin <sup>192)</sup>
1008	3 $\beta$ , 7 $\alpha$ -Dihydroxycholest-5-en-26-oic acid	Human-S <sup>16, 17)</sup> ; HSDD <sup>108)</sup> ; LD- S <sup>18)</sup> ; IMA-S <sup>17)</sup>	—
1009	3 $\alpha$ , 7 $\beta$ -Dihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147)</sup> , -F <sup>238)</sup>	1010 <sup>147)</sup>
1010	3 $\alpha$ , 7 $\beta$ -Dihydroxy-5 $\beta$ -cholest-24-en-26-oic acid	—	UDCA <sup>147)</sup>
1011	3 $\beta$ , 7 $\beta$ -Dihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator-F <sup>238)</sup>	—
1012	7 $\alpha$ -Hydroxy-3-oxocholest-4-en-26-oic acid	Human-S <sup>16, 17)</sup> ; LD-S <sup>18)</sup> ; IMA-S <sup>17)</sup> ; SH-S <sup>194)</sup>	—
1013	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator <sup>147, 237)</sup> , -F <sup>238)</sup>	DCA <sup>34, 56)</sup> ; 1014 <sup>147)</sup>
1014	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-5 $\beta$ -cholest-24-en-26-oic acid	—	DCA <sup>110, 147)</sup>
1015	3 $\beta$ , 12 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator-F <sup>238)</sup>	—
1016	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-24-methyl-27-nor-5 $\beta$ - cholestan-26-oic acid	—	CDCA <sup>138)</sup>
1017	3 $\alpha$ -Hydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator-F <sup>238)</sup> ; ZS-S <sup>205)</sup> ; COA-S <sup>114,</sup> 205)	LCA <sup>34)</sup> ; 1019 <sup>189)</sup>
1018	3 $\beta$ -Hydroxy-5 $\beta$ -cholestan-26-oic acid	Alligator-F <sup>238)</sup>	—
1019	3 $\alpha$ -Hydroxy-5 $\beta$ -cholest-24-en-26-oic acid	—	LCA <sup>110, 189)</sup>
1020	3 $\beta$ -Hydroxycholest-5-en-26-oic acid	Human-S <sup>16, 17)</sup> ; ZS <sup>205)</sup> , -S <sup>205)</sup> ; IMA-S <sup>17)</sup> ; COA <sup>205)</sup> , -S <sup>114, 205)</sup> ; LD- S <sup>18)</sup>	—

For abbreviations, see Table 1.


**Table 11.** C<sub>26</sub> and C<sub>25</sub> Bile acids

No.	Systematic name (Trivial name)	Natural source	Synthetic source
1101	(24R)- and (24S)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24-Tetrahydroxy-27-nor-5 $\beta$ -cholestan-26-oic acids	—	CAId <sup>167)</sup>
1102	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-27-nor-5 $\beta$ -cholestan-26-oic acid	—	CA <sup>31, 129)</sup> , NCA <sup>128)</sup>
1103	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\beta$ -cholestan-26-oic acid	—	CA <sup>54)</sup>
1104	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-Tetrahydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	NCAId <sup>103, 146)</sup>
1105	3 $\alpha$ , 6 $\beta$ , 7 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	1122 <sup>256)</sup>
1106	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\alpha$ -cholestan-25-oic acid (Allohomocholic acid)	Bullfrog*	ANCY <sup>90)</sup>
1107	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid (Homocholic acid)	Bullfrog*	CA <sup>31, 126, 207)</sup>
1108	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	1111 <sup>213)</sup>
1109	3 $\alpha$ , 7 $\beta$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\alpha$ -cholestan-25-oic acid	—	7-EACA <sup>9)</sup>
1110	3 $\alpha$ , 7 $\beta$ , 12 $\alpha$ -Trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	1112 <sup>168)</sup>
1111	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	HoCA <sup>213)</sup>
1112	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-7-oxo-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	HoCA <sup>168)</sup>
1113	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-26, 27-dinor-5 $\alpha$ -cholestan-25-oic acid	—	1117 <sup>87)</sup>
1114	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid (Homochenodeoxycholic acid)	—	CDCA <sup>40)</sup>
1115	3 $\alpha$ , 7 $\beta$ -Dihydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid (Homoursodeoxycholic acid)	—	UDCA <sup>168)</sup>
1116	3 $\alpha$ , 7 $\beta$ -Dihydroxy-26, 27-dinor-5 $\beta$ -cholest-11-en-25-oic acid	—	1110 <sup>168)</sup>
1117	7 $\alpha$ -Hydroxy-3-oxo-26, 27-dinor-5 $\alpha$ -cholestan-25-oic acid	—	HoCDCA <sup>87)</sup>
1118	7 $\alpha$ -Hydroxy-3-oxo-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	HoCDCA <sup>87, 116)</sup>
1119	7 $\alpha$ -Hydroxy-3-oxo-26, 27-dinorcholest-4-en-25-oic acid	—	1118 <sup>116)</sup>
1120	3 $\alpha$ -Hydroxy-7-oxo-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid	—	HoCDCA <sup>169)</sup>
1121	3 $\alpha$ -Hydroxy-26, 27-dinor-5 $\beta$ -cholestan-25-oic acid (Homolithocholic acid)	—	1120 <sup>169)</sup>
1122	3 $\alpha$ -Hydroxy-26, 27-dinor-5 $\beta$ -cholest-6-en-25-oic acid	—	CDCA <sup>256)</sup>

\*. Our unpublished observation. For abbreviations, see Table 1.

The occurrence of higher bile acids in nature was first demonstrated in 1934 by Shimizu and Oda who isolated a major bile acid from the bile of the toad, *Bufo vulgaris formosus*, to which they assigned the formula C<sub>28</sub>H<sub>46</sub>O<sub>5</sub>, and named it "trihydroxybufosterocholic acid"<sup>228)</sup>. Although

the nuclear structure (cholic acid type) and location of the double bond (between C-22 and C-23) of trihydroxybufosterocholic acid (XIII) were elucidated in 1936 from the fact that it gave bisnorcholic acid (XIV) upon ozonolysis (Fig. 6)<sup>229)</sup>, the structure of the terminal part of the side



**Fig. 6.** Structural determination of "trihydroxybufosterocholenic acid". XIII,  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholest-22-ene-24-carboxylic acid; XIV, bisnorcholeic acid; XV,  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestane-24-carboxylic acid;


chain had not been determined at that time. The structure of trihydroxybufosterocholenic acid was finally described in 1967 by Hoshita et al who synthesized  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestane-24-carboxylic acid (XV), which was identical with the hydrogenated derivative of trihydroxybufosterocholenic acid (XIII); hence the major bile acid of the toad was characterized as  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholest-22-ene-24-carboxylic acid (XIII) (Fig. 6)<sup>100</sup>. The stereochemistry of the side chain is still not yet established.

The natural occurrence of  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestan-26-oic acid was first demonstrated in 1939 in the bile of the bullfrog, *Rana catesbeiana*<sup>171</sup>, and later in various species of amphibians<sup>14, 154, 161, 178, 240, 242, 243, 257</sup>, all crocodians examined<sup>75</sup>, the kite, *Milvus lineatus lineatus*<sup>160</sup>, and even in healthy and diseased humans<sup>35, 58</sup>. This C<sub>27</sub> homolog of cholic acid has an asymmetric carbon atom at C-25; thus there are two stereoisomers. Most of the above-mentioned vertebrates have only (25R)- $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestan-26-oic acid (XVIII).

However, the bullfrog bile and the crocodile bile contain both 25R and 25S isomers<sup>178, 184</sup>. The occurrence of both 25R and 25S isomers in the same species at once arouses the suspicion that one is an artifact formed from the other. This is especially possible in the case of the crocodile in which the bile acids occur as taurine conjugates. Alkaline conditions necessary to hydrolyze the taurine-conjugated trihydroxy- $5\beta$ -cholestanoates might cause racemization at C-25. Une et al clearly showed that in the bullfrog both (25R)- and (25S)- $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestan-26-oic acids are authentic metabolites in this species<sup>243</sup>. Since all bile acids of the bullfrog bile occur in unconjugated form, they could be obtained without use of drastic procedures such as alkaline hydrolysis. High-performance liquid chromatographic analysis of the bile acid mixture of the bullfrog revealed that both 25R and 25S isomers occur in a ratio of about 20:1.

Patients with the cerebrohepato renal syndrome of Zellweger accumulate  $3\alpha,7\alpha,12\alpha$ -trihydroxy- $5\beta$ -cholestan-26-oic acid and other higher





**Fig. 7.** Structural determination of the second major bile acid of *Bufo vulgaris formosus*. XVI, (25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholest-23-en-26-oic acid; XVII, norcholic acid; XVIII, (25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid.


bile acids in their bile, serum, and urine as unusual metabolites of cholesterol<sup>68, 123</sup>). Une et al have reported that 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid excreted into the urine from an infant with Zellweger syndrome as the unconjugated form consisted of a mixture of the 25R and 25S isomers in the ratio of about 7:3<sup>246</sup>). Human liver is thought to synthesize only the 25R isomer (XVIII) of 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid as the biosynthetic precursor of cholic acid in normal conditions<sup>28</sup>). The formation of (25S)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid in Zellweger syndrome may reflect the operation of an unusual pathway of cholesterol catabolism in this unusual condition.

Okuda et al isolated a higher bile acid from the bile of the iguana, *Iguana iguana*, as a minor companion of allocholic acid, the major bile acid of this animal<sup>204</sup>). The structure of the minor bile acid of the iguana was deduced as the C<sub>27</sub> homolog of allocholic acid, 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\alpha$ -cholestan-26-oic acid by lithium aluminum hydride reduction to 5 $\alpha$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol<sup>204</sup>). The 5 $\alpha$ -C<sub>27</sub> bile acid was later pre-

pared from 5 $\alpha$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol<sup>117</sup>), and also found in the bile of some species of amphibians<sup>161,198,240,242</sup>). The stereochemistry at C-25 of the naturally occurring 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\alpha$ -cholestan-26-oic acid remained unknown. Kanemitsu isolated a minor bile acid from the bile of the turtle, *Amyda japonica*, and named "heterocholic acid"<sup>118</sup>). Our own observation has revealed that heterocholic acid is the 2:1 mixture of 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\alpha$ - and 5 $\beta$ -cholestan-26-oic acids.

A second major bile acid (XVI) from the bile of the toad, *Bufo vulgaris formosus*, was characterized as (25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholest-23-en-26-oic acid from the fact that the second major bile acid could be converted to norcholic acid (XVII) by oxidation and to (25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid (XVIII) by hydrogenation (Fig. 7)<sup>80,81</sup>). This unsaturated C<sub>27</sub> bile acid also occurs in the bile of another species of the toad, *Bufo marinus*, as a major bile acid<sup>257</sup>), and in the bile of the monitor lizard, *Varanus monitor*, as a minor constituent<sup>1</sup>).

In 1936, Yamasaki and Yuuki isolated a major



**Fig. 8.** Chemical conversion of the major bile acid of the turtle into a minor bile acid. XIX, (22S, 25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestano-26,22-lactone; XX, (22S,25R)-3 $\alpha$ ,12 $\alpha$ -dihydroxy-7-oxo-5 $\beta$ -cholestano-26,22-lactone; XXI, (22S,25R)-3 $\alpha$ ,12 $\alpha$ -dihydroxy-5 $\beta$ -cholestano-26,22-lactone. NBS, *N*-Bromosuccinimide.


bile acid of the turtle, *Amyda japonica*, as the lactone form, and named it "tetrahydroxysterocolanic lactone"<sup>252</sup>. The structure of tetrahydroxysterocolanic lactone was characterized as (22S,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestano-26,22-lactone (XIX) by <sup>1</sup>H-nuclear magnetic resonance spectrometry comparison with the reference compounds, four possible stereoisomers with respect to the C-22 and C-25 positions of 6 $\beta$ -methyl-3 $\alpha$ ,5-cyclo-5 $\alpha$ -cholestano-26,22-lactones<sup>62</sup>. Thus, the native higher bile acid of the turtle should be formulated as (22S,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid,

which was found in all turtles and tortoises examined as their major biliary constituent but not in any other vertebrate, and is now recognized as the characteristic component of the bile of the chelonians<sup>75</sup>.

3 $\alpha$ ,12 $\alpha$ ,22-Trihydroxy-5 $\beta$ -cholestan-26-oic acid was found in the bile of the green turtle, *Chelonia mydas* along with (22S, 25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid<sup>79</sup>. Our own observation has also revealed that 3 $\alpha$ ,12 $\alpha$ ,22-trihydroxy-5 $\beta$ -cholestan-26-oic acid is a minor companion of (22S,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid in the bile of the turtle, *Amyda japonica*. The stereochemistry of the side chain of 3 $\alpha$ ,12 $\alpha$ ,22-trihydroxy-5 $\beta$ -cholestan-26-oic acid is believed to be the same as that of (22S,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid because the lactone (XXI) of the former can be derived from the lactone (XIX) of the latter by the selective oxidation of 7 $\alpha$ -hydroxyl group followed by Huang-Minlon reduction of the resultant 7-oxo group to the methylene group (our unpublished observation) (Fig. 8).

Une et al have found two novel taurine-conjugated higher bile acids in urine from a patient with Zellweger syndrome<sup>246,247</sup>. These higher bile acids were obtained as the lactone form after alkaline hydrolysis followed by the extraction with ether of the acidified hydrolysate. The two steroidal lactones (XXIV, XXV) were treated with lithium aluminum hydride and the resultant reduction products (XXVI, XXVII) were identified as (22R,25R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22,26-pentol and (23R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,23,26-pentol by comparison with authentic compounds. These results indicate that the two native higher bile acids (XXII, XXIII) are (22R,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22- and (23R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,23-tetrahydroxy-5 $\beta$ -cholestan-26-oic acids, respectively (Fig. 9)<sup>247</sup>.

Varanic acid was isolated from the lizard, *Varanus niloticus*, from which the bile acid received its name, and characterized as a 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid<sup>41,69,109</sup>. Varanic acid or its diastereoisomers at C-24 and/or C-25 was found in the bile of several species of amphibians<sup>242,243</sup> and in the biological fluids of healthy and diseased humans<sup>175,205</sup>. Une et al synthesized all four stereoisomers at C-24 and C-25 of 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid<sup>241</sup>. Comparison with the synthetic varanic acids of known absolute configuration revealed that the varanic acid of the frog, *Bombina orientalis*, has the 24R, 25S configuration<sup>243</sup>. It is, however, still necessary to continue study of the stereochemistry of varanic acids; since Kinoshita et al also examined the stereochemistry of all four isomers at C-24 and C-25 of varanic acid and claimed the 24R, 25R configuration for the *Bombina* varanic acid<sup>152</sup>.



**Fig. 9.** Structural determination of two novel higher bile acids found in urine from patients with Zellweger syndrome. XXII, (22R,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid; XXIII, (23R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,23-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid; XXIV, (22R,25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26,22-lactone; XXV, (23R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26,23-lactone; XXVI, (22R,25R)-5 $\beta$ -cholestan-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,22,26-pentol; XXVII, (23R)-5 $\beta$ -cholestan-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,23,26-pentol.

According to current concepts, the major pathway for the biosynthesis of cholic acid (XXXI) in mammals involves a 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholest-24-en-26-oic acid and a 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid as the intermediates<sup>28,244</sup>. By direct comparison with the compounds of known absolute configuration, these intermediary higher bile acids were identified as (24E)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholest-24-en-26-oic acid (XXIX) and the 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid assigned by us to have the 24R, 25S configuration (Fig. 10)<sup>244</sup>.


3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -Trihydroxy-5 $\beta$ -cholest-24-en-26-oic acid has been detected in the bile of the lizard, *Varanus monitor*, as its minor constituent<sup>1</sup> and in the bile of healthy and diseased humans<sup>39,182</sup>.

The stereochemistry of the  $\Delta^{24}$ -double bond of the C<sub>27</sub> bile acid found in healthy human bile was determined as Z<sup>182</sup>, while a patient with thiolase deficiency contained both the 24E and 24Z isomers<sup>39</sup>.


An unusual C<sub>29</sub>-dicarboxylic bile acid, 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-27-carboxymethyl-5 $\beta$ -cholestan-26-oic acid (3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-27a,27b-dihomo-5 $\beta$ -cholestan-26,27b-dioic acid) (XXXII) was found in the serum of patients with Zellweger syndrome (Fig. 11)<sup>205</sup>. The structure has recently been confirmed by partial synthesis<sup>206</sup>.

#### Short Side Chain Bile Acids

Lester et al have claimed that the term "bile acids" should be applied to the steroids with a



**Fig. 10.** Postulated pathway for the biosynthesis of cholic acid. XXVIII, 5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -triol; III, (25R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol; XVIII, (25R)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid; XXIX, (24E)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholest-24-en-26-oic acid; XXX, (24R,25S)-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid; XXXI, cholic acid.



**Fig. 11.** 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -Trihydroxy-27-carboxymethyl-5 $\beta$ -cholestan-26-oic acid (XXXII).

side chain at C-17 ending in a carboxylic acid group<sup>176</sup>). However, etianic acid derivatives and pregnanoic acid derivatives are not termed "bile acids" in this review, since these C<sub>20</sub> and C<sub>21</sub> steroidal acids are biochemically related to steroid hormones rather than common C<sub>24</sub> bile acids. Thus, short side chain bile acids are here defined as C<sub>23</sub> and C<sub>22</sub> steroidal acids with one and two less carbon atoms in the side chain than common C<sub>24</sub> bile acids.

The prefixes "nor" and "dinor" are used for systematic names of C<sub>23</sub> and C<sub>22</sub> bile acids, respectively, while the prefix "bisnor" is used only for the trivial name of C<sub>22</sub> bile acids.

Tables 12 and 13 list most of the naturally occurring and chemically derived C<sub>23</sub> and C<sub>22</sub> bile acids with the shortened side chain. Specifically

**Table 12.** C<sub>23</sub> Bile acids

No.	Systematic name (Trivial name)	Natural source	Synthetic source
1201	1 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-24-nor-5 $\beta$ -cholan-23-oic acid	CTX-U <sup>170</sup> )	—
1202	2 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-24-nor-5 $\beta$ -cholan-23-oic acid	CTX-U <sup>170</sup> )	—
1203	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\alpha$ -cholan-23-oic acid (Allonorcholic acid)	Human <sup>182</sup> ); CTX <sup>144, 182</sup> ), -U <sup>144, 170</sup> )	1207 <sup>224</sup> )
1204	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Norcholic acid)	Human <sup>182</sup> ), -U <sup>2</sup> ), -M <sup>19</sup> ), -AF <sup>230</sup> ), -UCB <sup>230</sup> ); CTX <sup>144, 182</sup> ), -U <sup>144, 156, 170</sup> ); LD-U <sup>2, 7, 29, 230</sup> ), -S <sup>30, 230</sup> ); IMA-U <sup>3</sup> ); CHO-U <sup>236</sup> )	CA <sup>190, 217, 223, 224, 229, 233</sup> )
1205	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\alpha$ -cholan-23-oic acid	—	1207 <sup>224</sup> )
1206	3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid	—	1208 <sup>224</sup> )
1207	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-24-nor-5 $\alpha$ -cholan-23-oic acid	—	NCA <sup>224</sup> )
1208	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-24-nor-5 $\beta$ -cholan-23-oic acid	—	NCA <sup>195, 224</sup> )
1209	7 $\alpha$ , 12 $\alpha$ -Dihydroxy-3-oxo-24-norchol-4-en-23-oic acid	—	NCA <sup>224</sup> )
1210	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-7-oxo-24-nor-5 $\beta$ -cholan-23-oic acid	CTX <sup>182</sup> ), -U <sup>170</sup> )	NCA <sup>195</sup> )
1211	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-12-oxo-24-nor-5 $\beta$ -cholan-23-oic acid	CTX-U <sup>170</sup> )	NCA <sup>233</sup> )
1212	3 $\alpha$ -Hydroxy-7, 12-dioxo-24-nor-5 $\beta$ -cholan-23-oic acid	—	NCA <sup>233</sup> )
1213	3 $\alpha$ , 6 $\alpha$ -Dihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Norhyodeoxycholic acid)	—	HDCA <sup>151, 186, 217</sup> )
1214	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Norchenodeoxycholic acid)	Human <sup>182</sup> )	CDCA <sup>71, 113, 217</sup> )
1215	3 $\alpha$ , 7 $\beta$ -Dihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Norursodeoxycholic acid)	Human <sup>182</sup> ); CTX-U <sup>156</sup> )	UDCA <sup>156, 217</sup> ); 0512 <sup>182</sup> )
1216	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Nordeoxycholic acid)	—	DCA <sup>217</sup> ); 1210 <sup>195</sup> )
1217	3 $\alpha$ -Hydroxy-12-oxo-24-nor-5 $\beta$ -cholan-23-oic acid	—	NDCA <sup>218</sup> )
1218	3 $\alpha$ -Hydroxy-24-nor-5 $\beta$ -cholan-23-oic acid (Norlithocholic acid)	—	LCA <sup>212, 215, 217</sup> ); 1217 <sup>218</sup> )
1219	3 $\beta$ -Hydroxy-24-nor-5 $\beta$ -cholan-23-oic acid	—	NLCA <sup>212</sup> )
1220	3 $\beta$ -Hydroxy-24-norchol-5-en-23-oic acid	—	1313 <sup>232</sup> )

For abbreviations, see Table 1.

**Table 13.** C<sub>22</sub> Bile acids

No.	Systematic name (Trivial name)	Natural source	Synthetic source
1301	1 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	CTX-U <sup>170)</sup>	—
1302	2 $\beta$ , 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Tetrahydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	CTX-U <sup>170)</sup>	—
1303	3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -Trihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid (Bisnorcholic acid)	CTX <sup>182)</sup> , -U <sup>170)</sup>	NCA <sup>190, 229, 234)</sup>
1304	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-7-oxo-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	CTX-U <sup>170)</sup>	BNCA <sup>170)</sup>
1305	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-12-oxo-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	CTX-U <sup>170)</sup>	BNCA <sup>170, 234)</sup>
1306	3 $\alpha$ , 6 $\alpha$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid (Bisnorhyodeoxycholic acid)	—	NHDCA <sup>151, 186)</sup>
1307	3 $\alpha$ , 7 $\alpha$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid (Bisnorchenodeoxycholic acid)	—	NCDCA <sup>113)</sup> , 1305 <sup>99)</sup>
1308	3 $\alpha$ , 12 $\alpha$ -Dihydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid (Bisnordeoxycholic acid)	—	NDCA <sup>124)</sup>
1309	3 $\alpha$ -Hydroxy-12-oxo-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	—	BNDCA <sup>218)</sup>
1310	3 $\alpha$ -Hydroxy-23, 24-dinor-5 $\alpha$ -cholan-22-oic acid or 3 $\beta$ -Hydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid	Human-S <sup>211)</sup>	1313 <sup>210)</sup>
1311	3 $\alpha$ -Hydroxy-23, 24-dinor-5 $\beta$ -cholan-22-oic acid (Bisnorlithocholic acid)	Human-M <sup>210)</sup>	1313 <sup>210)</sup>
1312	3 $\beta$ -Hydroxy-23, 24-dinor-5 $\alpha$ -cholan-22-oic acid	Human-S <sup>211)</sup>	1313 <sup>210)</sup>
1313	3 $\beta$ -Hydroxy-23, 24-dinorchol-5-en-22-oic acid	Human-S <sup>211)</sup> , -M <sup>210)</sup>	Stigmasterol <sup>160)</sup>

For abbreviations, see Table 1.

excluded are 11-oxygenated derivatives and  $\Delta^{20(22)}$ -norcholenoic acids, which had some passing importance in the manufacture of steroid hormones. It has been known that some microorganisms degraded cholesterol and C<sub>24</sub> bile acids to bisnorcholanoic acid derivatives. However, these microbial metabolites are not included in the tables.

The first recognition of the natural occurrence of bile acids with the shortened side chain came from the studies, in 1977, of Alme et al who found a trace amount of unconjugated norcholic acid (XVII) in urine from healthy and liver diseased humans<sup>2)</sup>. In healthy humans, the C<sub>23</sub> bile acid (XVII) is thought to be formed from the corresponding C<sub>24</sub> bile acid, cholic acid (XXXI), by shortening of the side chain by one carbon atom

( $\alpha$ -oxidation) (Fig. 12). Matoba et al<sup>182)</sup> and Kuramoto et al<sup>170)</sup> have found a relatively large amount of C<sub>23</sub> and C<sub>22</sub> bile acids in the bile and urine from patients with CTX, respectively. It seems unlikely that these short side chain bile acids are derived from common C<sub>24</sub> bile acids by  $\alpha$ - and  $\beta$ -oxidations, since the production of C<sub>24</sub> bile acids is below normal in this disease. We postulate, therefore, that the increased formation of the short side chain bile acids in CTX is ascribed to the degradation of some 22- and 23-hydroxylated bile alcohols (e.g. VI) which are synthesized unusually in patients with CTX (Fig. 12).

(Received February 28, 1994)




Fig. 12. Postulated pathways for the formation of norcholic acid in healthy persons and in patients with CTX. XXXI, cholic acid; XVII, norcholic acid; VI, (23R)-5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,23-tetrol.

## REFERENCES

1. Ali, S.S., Stephenson, E. and Elliott, W.H. 1982. Bile acids. LXVII. The major bile acids of *Varanus monitor*. *J. Lipid Res.* **23**: 947-954.
2. Alme, B., Bremmelgaard, A., Sjøvall, J. and Thomassen, P. 1977. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas-liquid chromatography-mass spectrometry. *J. Lipid Res.* **18**: 339-362.
3. Alme, B., Norden, A. and Sjøvall, J. 1978. Glucuronides of unconjugated 6-hydroxylated bile acids in urine of a patient with malabsorption. *Clin. Chim. Acta* **86**: 251-259.
4. Amimoto, K., Hoshita, T. and Kazuno, T. 1965. Studies on the bile of the turtle. *J. Biochem.* **57**: 565-570.
5. Amimoto, K. 1966. Bile salts of the salamander, *Megalobatrachus japonicus*. *J. Biochem.* **59**: 340-343.
6. Amos, B., Anderson, I.G., Haslewood, G.A.D. and Tokes, L. 1977. Bile salts of the lungfishes *Lepidosiren*, *Neoceratodus* and *Protopterus* and those of the coelacanth *Latimeria chalumnae* Smith. *Biochem. J.* **161**: 201-204.
7. Amuro, Y., Hayashi, E., Endo, T., Higashino, K. and Kishimoto, S. 1983. Unusual trihydroxylated bile acids in urine of patients with liver cirrhosis. *Clin. Chim. Acta* **127**: 61-67.
8. Anderson, I.G. and Haslewood, G.A.D. 1962. Comparative studies of 'bile salts'. 15. The natural occurrence and preparation of allocholic acid. *Biochem. J.* **85**: 236-242.
9. Anderson, I.G., Briggs, T. and Haslewood, G.A.D. 1964. Comparative studies of 'bile salts'. 18. The chemistry of cyprinol. *Biochem. J.* **90**: 303-308.
10. Anderson, I.G. and Haslewood, G.A.D. 1964. Comparative studies of 'bile salts'. 20. Bile salts of the coelacanth, *Latimeria chalumnae* Smith. *Biochem. J.* **93**: 34-39.
11. Anderson, I.G., Haslewood, G.A.D., Cross, A.D. and Tokes, L. 1967. New evidence for the structure of myxinol. *Biochem. J.* **104**: 1061-1063.
12. Anderson, I.G. and Haslewood, G.A.D. 1969. Comparative studies of 'bile salts'. 16-Deoxymyxinol, a second bile alcohol from hagfish. *Biochem. J.* **112**: 763-765.
13. Anderson, I.G. and Haslewood, G.A.D. 1970. Comparative studies of 'bile salts'. 5 $\alpha$ -Chimaerol, a new bile alcohol from the white sucker *Catostomus commersoni* Lacepede. *Biochem. J.* **116**: 581-587.
14. Anderson, I.G., Haslewood, G.A.D., Oldham, R.S., Amos, B. and Tokes, L. 1974. A more detailed study of bile salt evolution, including techniques for small-scale identification and their application to amphibian biles. *Biochem. J.* **141**: 485-494.
15. Anderson, I.G., Banister, K.E., Haslewood,

- G.A.D., Cho, D. and Tokes, L.** 1980. Bile salts of fishes collected on the Zaire river expedition (1974–5): their chemical nature and its possible significance. *Zool. J. Linn. Soc.* **68**: 41–51.
16. **Axelsson, M., Mork, B. and Sjøvall, J.** 1988. Occurrence of 3 $\beta$ -hydroxy-5-cholestenoic acid, 3 $\beta$ ,7 $\alpha$ -dihydroxy-5-cholestenoic acid, and 7 $\alpha$ -hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood. *J. Lipid Res.* **29**: 629–641.
  17. **Axelsson, M., Mork, B., Aly, A., Walldius, G. and Sjøvall, J.** 1989. Concentrations of cholestenic acids in plasma from patients with reduced intestinal reabsorption of bile acids. *J. Lipid Res.* **30**: 1883–1887.
  18. **Axelsson, M., Mork, B., Aly, A., Wisen, O. and Sjøvall, J.** 1989. Concentrations of cholestenic acids in plasma from patients with liver disease. *J. Lipid Res.* **30**: 1877–1882.
  19. **Back, P. and Walter, K.** 1980. Developmental pattern of bile acid metabolism as revealed by bile acid analysis of meconium. *Gastroenterology* **78**: 671–676.
  20. **Batta, A.K., Dayal, B., Tint, G.S., Shefer, S., Toome, V., Salen, G. and Mosbach, E.H.** 1978. Preparation and characterization of (24R and 24S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 24, 25-tetrols and (24R and 24S)-5 $\beta$ -cholestane-3 $\alpha$ , 24, 25-triols. *Steroids* **31**: 99–111.
  21. **Batta, A.K., Salen, G., Tint, G.S. and Shefer, S.** 1979. Improved synthesis of 5 $\beta$ -cholestan-26-oic acids. *Steroids* **33**: 589–594.
  22. **Batta, A.K., Salen, G., Blount, J.F. and Shefer, S.** 1979. Configuration at C-25 in 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid by X-ray crystallography. *J. Lipid Res.* **20**: 935–940.
  23. **Batta, A.K., Tint, G.S., Dayal, B., Shefer, S. and Salen, G.** 1982. Improved synthesis of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ -tetrahydroxy-5 $\beta$ -cholestan-26-oic acid. *Steroids* **39**: 693–702.
  24. **Batta, A.K., Salen, G., Shefer, S., Dayal, B. and Tint, G.S.** 1983. Configuration at C-25 in 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid isolated from human bile. *J. Lipid Res.* **24**: 94–96.
  25. **Batta, A.K., Mirchandani, R., Salen, G. and Shefer, S.** 1992. Synthesis of 3 $\alpha$ , 7 $\alpha$ -dihydroxy-5 $\beta$ -cholestan-26-oic acid from 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid: configuration in the bile of *Alligator mississippiensis*. *Steroids* **57**: 162–166.
  26. **Bergstrom, S., Paabo, K. and Rumpf, J.A.** 1954. Synthesis and metabolism of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$  [4-<sup>14</sup>C] coprostane. *Acta Chem. Scand.* **8**: 1109–1110.
  27. **Berseus, O., Danielsson, H. and Kallner, A.** 1965. Synthesis and metabolism of cholest-4-ene-7 $\alpha$ ,12 $\alpha$ -diol-3-one and 5 $\beta$ -cholestane-7 $\alpha$ ,12 $\alpha$ -diol-3-one. *J. Biol. Chem.* **240**: 2396–2401.
  28. **Bjorkhem, I.** 1992. Mechanism of degradation of the steroid side chain in the formation of bile acids. *J. Lipid Res.* **33**: 455–471.
  29. **Bremmelgaard, A. and Sjøvall, J.** 1979. Bile acid profiles in urine of patients with liver diseases. *Eur. J. Clin. Invest.* **9**: 341–348.
  30. **Bremmelgaard, A. and Alme, B.** 1980. Analysis of plasma bile acid profiles in patients with liver diseases associated with cholestasis. *Scand. J. Gastroent.* **15**: 593–600.
  31. **Bridgwater, R.J.** 1956. Partial synthesis of the two 3 $\alpha$ :7 $\alpha$ :12 $\alpha$ -trihydroxycoprostanic acids and of similar bile acids with extended side chains. *Biochem. J.* **64**: 593–599.
  32. **Bridgwater, R.J., Briggs, T. and Haslewood, G.A.D.** 1962. Comparative studies of 'bile salts'. 14. Isolation from shark bile and partial synthesis of scymnol. *Biochem. J.* **82**: 285–290.
  33. **Bridgwater, R.J., Haslewood, G.A.D. and Watt, J.R.** 1963. Comparative studies of 'bile salts'. 17. A bile alcohol from *Chimaera monstrosa*. *Biochem. J.* **87**: 28–31.
  34. **Briggs, T.** 1970. Partial synthesis of 25D- and 25L-cholestanoic acids from some common bile acids. *J. Org. Chem.* **35**: 1431–1434.
  35. **Carey, Jr., J.B. and Haslewood, G.A.D.** 1963. Crystallization of trihydroxycoprostanic acid from human bile. *J. Biol. Chem.* **238**: PC855–856.
  36. **Carlson, G.L., Belobaba, D.T.E., Hofmann, A.F. and Wedmid, Y.** 1977. 24-Nor-5 $\beta$ -chol-22-enes derived from the major bile acids by oxidative decarboxylation. *Steroids* **30**: 787–793.
  37. **Clayton, P.T., Muller, D.P.R. and Lawson, A.M.** 1982. The bile acid composition of gastric contents from neonates with high intestinal obstruction. *Biochem. J.* **206**: 489–498.
  38. **Clayton, P.T., Lake, B.D., Hall, N.A., Shortland, D.B., Carruthers, R.A. and Lawson, A.M.** 1987. Plasma bile acids in patients with peroxisomal dysfunction syndromes: analysis by capillary gas chromatography-mass spectrometry. *Eur. J. Pediat.* **146**: 166–173.
  39. **Clayton, P.T., Patel, E., Lawson, A.M., Carruthers, R.A. and Collins, J.** 1990. Bile acid profiles in peroxisomal 3-oxoacyl-Coenzyme A thiolase deficiency. *J. Clin. Invest.* **85**: 1267–1273.
  40. **Cohen, B.I., Tint, G.S., Kuramoto, T. and Mosbach, E.H.** 1975. New bile alcohols--Synthesis of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 25-triol and 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 25-24(<sup>14</sup>C)-triol. *Steroids* **25**: 365–378.
  41. **Collings, B.G. and Haslewood, G.A.D.** 1966. The chemical nature of varanic acid. *Biochem. J.* **99**: 50p.
  42. **Cross, A.D.** 1961. Scymnol sulfate and anhydroscymnol. *J. Chem. Soc.* 2817–2821.
  43. **Cross, A.D., Landis, P.W. and Murphy, J.W.** 1965. *Steroids* CCLXXVII. Spectra and stereochemistry XIX. A comparative study of the NMR spectra of some steroids in five solvents. The structure of 'Acipenserol-A'. *Steroids* **5**: 655–662.
  44. **Dayal, B., Shefer, S., Tint, G.S., Salen, G. and Mosbach, E.H.** 1976. Synthesis of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol and 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 25-pentol. *J. Lipid Res.* **17**: 74–77.
  45. **Dayal, B., Shefer, S., Tint, G.S., Salen, G. and Mosbach, E.H.** 1976. C<sub>26</sub>-Analogues of naturally occurring C<sub>27</sub> bile alcohols. *J. Lipid Res.* **17**: 478–484.
  46. **Dayal, B., Salen, G., Tint, G.S., Toome, V., Shefer, S. and Mosbach, E.H.** 1978. Absolute configuration of pentahydroxy bile alcohols excreted by patients with cerebrotendinous xanthomatosis: a circular dichroism study. *J. Lipid*



- Res. **19**: 187–190.
47. **Dayal, B., Batta, A.K., Shefer, S., Tint, G.S., Salen, G. and Mosbach, E.H.** 1978. Preparation of 24(R)- and 24(S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 24-triols and 25(R)- and 25(S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 26-triols by a hydroboration procedure. *J. Lipid Res.* **19**: 191–196.
  48. **Dayal, B., Batta, A.K., Shefer, S., Tint, G.S. and Salen, G.** 1978. Synthesis of biological precursors of cholic acid. *Steroids* **32**: 337–344.
  49. **Dayal, B., Tint, G.S. and Salen, G.** 1979. C<sub>26</sub>-Analogues of naturally occurring bile alcohols-II. Preparation of 24-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrols (23R and 23S) and 24-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrols (25R and 25S) by a hydroboration procedure. *Steroids* **34**: 581–588.
  50. **Dayal, B., Bagan, E., Speck, J. and Salen, G.** 1980. A facile synthesis of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol. *Steroids* **35**: 439–444.
  51. **Dayal, B., Tint, G.S., Batta, A.K., Shefer, S. and Salen, G.** 1981. Synthesis of biological precursors of cholic acid II. *Steroids* **37**: 205–211.
  52. **Dayal, B., Tint, G.S., Greeley, D.N., Williams, T.H. and Salen, G.** 1983. Identification of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol in cerebrotendinous xanthomatosis. *Steroids* **42**: 441–448.
  53. **Dayal, B., Greeley, D.N., Williams, T.H., Tint, G.S. and Salen, G.** 1984. Stereospecific synthesis of 3 $\beta$ -hydroxylated bile alcohols. *J. Lipid Res.* **25**: 646–650.
  54. **Dayal, B., Salen, G., Tint, G.S., Batta, A.K. and Shefer, S.** 1984. Synthesis of the putative metabolites of plant sterols: (24R)- and (24S)-24-methyl-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrols and 24-ethyl-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ -tetrol. *J. Lipid Res.* **25**: 865–870.
  55. **Dayal, B., Tint, G.S., Toome, V., Batta, A.K., Shefer, S. and Salen, G.** 1985. Synthesis and structure of 26 (or 27)-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24S, 25 $\xi$ -pentol isolated from the urine and feces of a patient with sitosterolemia and xanthomatosis. *J. Lipid Res.* **26**: 298–305.
  56. **Deen, P.D.G. and Aplin, R.T.** 1966. Mass spectrometric studies on bile acids: The differentiation between chenodeoxycholic acid and deoxycholic acid and the identification of 3 $\alpha$ , 7 $\alpha$ -dihydroxy-5 $\beta$ -cholestanoic acid in alligator bile. *Steroids* **8**: 565–579.
  57. **Deleze, G., Bjorkhem, I. and Karlaganis, G.** 1986. Bile acids and bile alcohols in two patients with Zellweger (cerebro-hepato-renal) syndrome. *J. Pediat. Gastroenterol. Nutr.* **5**: 701–710.
  58. **Eyssen, H., Parmentier, G., Compennolle, F., Boon, J. and Eggermont, E.** 1972. Trihydroxycoprostanic acid in the duodenal fluid of two children with intrahepatic bile duct anomalies. *Biochim. Biophys. Acta* **273**: 212–221.
  59. **Eyssen, H., Eggermont, E., van Eldere, J., Jaeken, J., Parmentier, G. and Janssen, G.** 1985. Bile acid abnormalities and the diagnosis of cerebro-hepato-renal syndrome (Zellweger syndrome). *Acta Pediat. Scand.* **74**: 539–544.
  60. **Fernholz, E.** 1933. Uber die Konstitution des Stigmasterins. *Liebigs Ann. Chem.* **507**: 128–138.
  61. **Fieser, L.F. and Fieser, M.** 1959. Bile acids and alcohols. p. 421–443. *In* *Steroids*, Reinhold Publishing Corporation, New York.
  62. **Fujimoto, Y., Iwadate, H., Ikekawa, N., Kihira, K. and Hoshita, T.** 1985. Structure of the steroidal lactone isolated from turtle bile: (22S, 25R)-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestano-26, 22-lactone. *J. Chem. Soc. Perkin Trans. I.* 2701–2704.
  63. **Gengenbacher, T., Gerok, W., Giese, U. and Kurz, G.** 1990. Synthesis and applicability of photolabile 7, 7-azo analogues of natural bile salt precursors. *J. Lipid Res.* **31**: 315–327.
  64. **Gustafsson, J., Sisfontes, L. and Bjorkhem, I.** 1987. Diagnosis of Zellweger syndrome by analysis of bile acids and plasmalogens in stored dried blood collected at neonatal screening. *J. Pediat.* **111**: 264–267.
  65. **Hammarsten, O.** 1898. Ueber eine neue Gruppe gepaarter Gallensaure. *Z. Physiol. Chem.* **24**: 322–350.
  66. **Hanson, R.F. and Williams, G.** 1971. The isolation and identification of 3 $\alpha$ , 7 $\alpha$ -dihydroxy-5 $\beta$ -cholestan-26-oic acid from human bile. *Biochem. J.* **121**: 863–864.
  67. **Hanson, R.F., Isenberg, J.N., Williams, G.C., Hachey, D., Szczepanik, P., Klein, P.D. and Sharp, H.L.** 1975. The metabolism of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid in two siblings with cholestasis due to intrahepatic bile duct anomalies. *J. Clin. Invest.* **56**: 577–587.
  68. **Hanson, R.F., Szczepanik-Van Leeuwen, P., Williams, G.C., Grabowski, G. and Sharp, H.L.** 1979. Defects of bile acid synthesis in Zellweger's syndrome. *Science* **203**: 1107–1108.
  69. **Haslewood, G.A.D. and Wootton, V.** 1950. Comparative studies of 'bile salts'. 1. Preliminary survey. *Biochem. J.* **47**: 584–597.
  70. **Haslewood, G.A.D.** 1952. Comparative studies of 'bile salts'. 5. Bile salts of Crocodylidae. *Biochem. J.* **52**: 583–587.
  71. **Haslewood, G.A.D.** 1961. Comparative studies of 'bile salts'. 13. Bile acids of the leopard seal, *Hydrurga leptonyx*, and of two snakes of the genus *Bitis*. *Biochem. J.* **78**: 352–359.
  72. **Haslewood, G.A.D.** 1964. Comparative studies of 'bile salts'. 19. The chemistry of ranol. *Biochem. J.* **90**: 309–313.
  73. **Haslewood, G.A.D.** 1966. Comparative studies of 'bile salts'. Myxinol disulfate, the principal bile salt of hagfish (*Mixinidae*). *Biochem. J.* **100**: 233–237.
  74. **Haslewood, G.A.D.** 1967. Bile salt evolution. *J. Lipid Res.* **8**: 535–550.
  75. **Haslewood, G.A.D.** 1967. Bile salts. p. 1–116., Methuen Co. Ltd., London.
  76. **Haslewood, G.A.D. and Tammer, A.R.** 1968. Comparative studies of bile salts. Bile salts of sturgeons (Acipenseridae) and of the paddlefish *Polyodon spathula*: A new partial synthesis of 5 $\beta$ -cyprinol. *Biochem. J.* **108**: 263–268.
  77. **Haslewood, G.A.D. and Tokes, L.** 1969. Comparative studies of bile salts. Bile salts of the lamprey *Petromyzon marinus* L. *Biochem. J.* **114**: 179–184.
  78. **Haslewood, G.A.D. and Tokes, L.** 1972. Comparative studies of bile salts. A new type of bile

- salt from *Arapaima gigas* (Cuvier) (Family Osteoglossidae). *Biochem. J.* **126**: 1161–1170.
79. **Haslewood, G.A.D., Ikawa, S., Tokes, L. and Wong, D.** 1978. Bile salts of the green turtle *Chelonia mydas* (L.). *Biochem. J.* **171**: 409–412.
  80. **Hayakawa, S.** 1953. Studies on bile salts of toad (*Bufo vulgaris japonicus*). X. Separation of  $\Delta^{23}$ -3( $\alpha$ ), 7( $\alpha$ ), 12( $\alpha$ )-trihydroxycoprostenic acid. *Proc. Japan Acad.* **29**: 279–284.
  81. **Hayakawa, S.** 1953. Studies on bile salts of toad (*Bufo vulgaris japonicus*). XI. Formation of norcholic acid from  $\Delta^{23}$ -3( $\alpha$ ),7( $\alpha$ ),12( $\alpha$ )-trihydroxycoprostenic acid  $C_{27}H_{44}O_5$  and stem acid  $C_{27}H_{46}O_2$ . *Proc. Japan Acad.* **29**: 285–288.
  82. **Hiraoka, T., Kihira, K., Kajiyama, G., Kuramoto, T. and Hoshita, T.** 1987. Identification of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24, 25, 26-hexol in human urine. *J. Lipid Res.* **28**: 895–899.
  83. **Hiraoka, T., Kihira, K., Kohda, T., Kosaka, D., Kajiyama, G. and Hoshita, T.** 1987. Urinary bile alcohols in liver dysfunction. *Clin. Chim. Acta* **169**: 127–132.
  84. **Hiraoka, T., Kihira, K., Kosaka, D., Kohda, T., Hoshita, T. and Kajiyama, G.** 1988. Identification of bile alcohols in serum from healthy humans. *Steroids* **51**: 543–550.
  85. **Hiraoka, T., Kosaka, D., Kajiyama, G., Kohda, T., Funakura, T., Yamauchi, T., Kihira, K. and Hoshita, T.** 1988. Measurement of serum bile alcohol levels in liver dysfunction, using isotope dilution-mass spectrometry. *Scand. J. Gastroenterol.* **23**: 821–826.
  86. **Hiraoka, T., Kohda, T., Kosaka, D., Yamauchi, T., Kihira, K., Kuramoto, T., Hoshita, T. and Kajiyama, G.** 1989. Identification of bile alcohols in rat bile. *J. Lipid Res.* **30**: 1889–1893.
  87. **Hiremath, S.V. and Elliott, W.H.** 1981. Bile acids. LXIV. Synthesis of 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 25-triol and esters of new 5 $\alpha$ -bile acids. *Steroids* **38**: 465–475.
  88. **Hoshita, N. and Okuda, K.** 1967. Partial synthesis of stero-bile acids related to chenodeoxycholic acid. *J. Biochem.* **62**: 655–657
  89. **Hoshita, T.** 1959. The partial synthesis of trihydroxy-24-methylcoprostanic acid. *J. Biochem.* **46**: 507–511.
  90. **Hoshita, T.** 1962. Isolation of a new bile sterol, 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-26, 27-epoxycholestane from carp bile. *J. Biochem.* **52**: 125–130.
  91. **Hoshita, T.** 1962. Syntheses of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25 $\xi$ , 26- and 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 25-pentahydroxycoprostanes. *J. Biochem.* **52**: 176–179.
  92. **Hoshita, T., Kouchi, M. and Kazuno, T.** 1963. Synthesis of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentahydroxycoprostanane. *J. Biochem.* **53**: 291–294.
  93. **Hoshita, T., Nagayoshi, S. and Kazuno, T.** 1963. Studies on the bile of carp. *J. Biochem.* **54**: 369–374.
  94. **Hoshita, T., Nagayoshi, S., Kouchi, M. and Kazuno, T.** 1964. Studies on the bile of the family *Cyprinidae*. *J. Biochem.* **56**: 177–181.
  95. **Hoshita, T., Yukawa, M. and Kazuno, T.** 1964. The isolation of a new bile alcohol, 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentol from the bile of *Conger myriaster*. *Steroids* **4**: 569–574.
  96. **Hoshita, T., Sasaki, T. and Kazuno, T.** 1965. Isolation of a bile alcohol, 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrol from carp bile. *Steroids* **5**: 241–247.
  97. **Hoshita, T., Sasaki, T., Tanaka, Y., Betsuki, S. and Kazuno, T.** 1965. Biosynthesis of bile acids and bile alcohols in toad. *J. Biochem.* **57**: 751–757.
  98. **Hoshita, T., Hirofuji, S., Nakagawa, T. and Kazuno, T.** 1967. Studies on the bile salts of the newt and synthesis of 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol (5 $\alpha$ -bufol). *J. Biochem.* **62**: 62–66.
  99. **Hoshita, T., Hirofuji, S., Sasaki, T. and Kazuno, T.** 1967. Isolation of a new bile acid, haemulcholic acid from the bile of *Parapristipoma trilineatum*. *J. Biochem.* **61**: 136–141.
  100. **Hoshita, T., Okuda, K. and Kazuno, T.** 1967. Synthesis of 3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ -trihydroxy-5 $\beta$ -cholestane-24-carboxylic acid and the chemical structure of trihydroxybufosterocholenic acid isolated from toad bile. *J. Biochem.* **61**: 756–759.
  101. **Hoshita, T. and Kazuno, T.** 1968. Chemistry and metabolism of bile alcohols and higher bile acids. p. 207–254. *In* Paoletti, R. and Kritchevsky, D. (eds.), *Advances in Lipid Research*. Vol 6., Academic Press, Inc., New York.
  102. **Hoshita, T., Shefer, S. and Mosbach, E.H.** 1968. Conversion of 7 $\alpha$ , 12 $\alpha$ -dihydroxycholest-4-en-3-one to 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triol by iguana liver microsomes. *J. Lipid Res.* **9**: 237–243.
  103. **Hoshita, T., Yasuhara, M., Kihira, K. and Kuramoto, T.** 1976. Identification of (23S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol in cerebrotendinous xanthomatosis. *Steroids* **27**: 657–664.
  104. **Hoshita, T., Yasuhara, M., Une, M., Kibe, A., Itoga, E., Kito, S. and Kuramoto, T.** 1980. Occurrence of bile alcohol glucuronides in bile of patients with cerebrotendinous xanthomatosis. *J. Lipid Res.* **21**: 1015–1021.
  105. **Hoshita, T.** 1985. Bile alcohols and primitive bile acids. p. 279–302. *In* Danielsson, H. and Sjovall, J. (eds.), *Sterols and bile acids*. New comprehensive biochemistry. Vol 12, Elsevier, Amsterdam.
  106. **Ichimiya, H., Yanagisawa, J. and Nakayama, F.** 1984. Significance of bile alcohol in urine of a patient with cholestasis: Identification of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26, 27-pentol (5 $\beta$ -cypriinol) and 5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol (27-deoxy-5 $\beta$ -cypriinol). *Chem. Pharm. Bull.* **32**: 2874–2877.
  107. **Ichimiya, H., Yanagisawa, J. and Nakayama, F.** 1987. Altered metabolism of bile alcohol and bile acid in complete extrahepatic cholestasis: qualitative and quantitative aspects. *J. Lipid Res.* **28**: 1028–1037.
  108. **Ichimiya, H., Egestad, B., Nazer, H., Baginski, E.S., Clayton, P.T. and Sjovall, J.** 1991. Bile acids and bile alcohols in a child with hepatic 3 $\beta$ -hydroxy- $\Delta^5$ - $C_{27}$ -steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment. *J. Lipid Res.* **32**: 829–841.
  109. **Inai, Y., Tanaka, Y., Betsuki, S. and Kazuno, T.** 1964. Synthesis of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ -tetrahydroxycoprostanic acid. *J. Biochem.* **56**: 591–593.
  110. **Iqbal, M.N., Patrick, P.H. and Elliott, W.H.** 1991. Bile acids. LXXXI. Synthesis and structural assignment of E/Z isomers of substituted methyl

- hydroxy-5 $\beta$ -cholest-24-en-26-oates. *Steroids* **56**: 505–512.
111. **Ishida, H., Yamaguchi, T., Natsuyama, R., Tsuji, K. and Kosuge, T.** 1988. Study on the bile salt sodium scymnol sulfate, from *Rhizoprionodon acutus*. *Chem. Pharm. Bull.* **36**: 4408–4413.
112. **Ishida, H., Kinoshita, S., Natsuyama, R., Nukaya, H., Tsuji, K., Kosuge, T. and Yamaguchi, K.** 1991. Study on the bile salt, sodium scymnol sulfate, from *Rhizoprionodon acutus*. II. The structures of scymnol, anhydroscymnol and sodium scymnol sulfate. *Chem. Pharm. Bull.* **39**: 3153–3156.
113. **Ishihara, T.** 1937. Über den systematischen Abbau der Chenodesoxycholsäure. *J. Biochem.* **27**: 265–277.
114. **Janssen, G. and Parmentier, G.** 1981. A further study of the bile acids in infants with coprostanic acidemia. *Steroids* **37**: 81–89.
115. **Janssen, G., Toppet, S. and Parmentier, G.** 1982. Structure of the side chain of the C<sub>29</sub> dicarboxylic acid occurring in infants with coprostanic acidemia. *J. Lipid Res.* **23**: 456–465.
116. **Joyce, M.J., Hiremath, S.V., Mattammal, M.B. and Elliott, W.H.** 1984. Bile acids. LXXIII. Synthesis of analogs of 7 $\alpha$ -hydroxy-4-cholesten-3-one as substrates for hepatic steroid 12 $\alpha$ -hydroxylase. *Steroids* **44**: 95–101.
117. **Kamat, S.Y. and Elliott, W.H.** 1972. Bile acids XXXVI. Synthesis of 5 $\alpha$ -cholestan-26-oic acids. *Steroids* **20**: 279–294.
118. **Kanemitsu, T.** 1942. Über eine isomere Cholsäure, Heterocholsäure aus der Alligatorschildkrotengalle. *J. Biochem.* **35**: 409–412.
119. **Karlaganis, G., Alme, B., Karlaganis, V. and Sjøvall, J.** 1981. Bile alcohol glucuronides in urine. Identification of 27-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 25 $\xi$ -pentol in man. *J. Steroid Biochem.* **14**: 341–345.
120. **Karlaganis, G., Karlaganis, V. and Sjøvall, J.** 1984. Identification of 27-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 25 $\xi$ , 26-hexol and partial characterization of the bile alcohol profile in urine. *J. Lipid Res.* **25**: 693–702.
121. **Karlaganis, G., Bradley, S.E., Boyer, J.L., Batta, A.K., Salen, G., Egestad, B. and Sjøvall, J.** 1989. A bile alcohol sulfate as a major component in the bile of the small skate (*Raja erinacea*). *J. Lipid Res.* **30**: 317–322.
122. **Kase, B.F., Bjorkhem, I., Haga, P. and Pedersen, J.I.** 1985. Defective peroxisomal cleavage of the C<sub>27</sub>-steroid side chain in the cerebro-hepato-renal syndrome of Zellweger. *J. Clin. Invest.* **75**: 427–435.
123. **Kase, B.F., Pedersen, J.I., Strandvik, B. and Bjorkhem, I.** 1985. In vivo and in vitro studies on formation of bile acids in patients with Zellweger syndrome. *J. Clin. Invest.* **76**: 2393–2402.
124. **Kazuno, T. and Shimizu, T.** 1939. Über den Abbau der Desoxycholsäure zu Dioxyketon C<sub>19</sub>H<sub>32</sub>O<sub>3</sub> und 22-Methyl-3,12-diketonorcholen(20). *J. Biochem.* **29**: 421–433
125. **Kazuno, T., Moori, A., Sasaki, K., Kuroda, M. and Mizuguchi, M.** 1952. The synthesis of cholane, trihydroxycholane and trihydroxyhomocho-
- lane. *Proc. Japan Acad.* **28**: 416–423.
126. **Kazuno, T., Moori, A., Sasaki, K. and Mizuguchi, M.** 1952. The synthesis of trihydroxybisnorsterocholane and homocholeic acid. *Proc. Japan Acad.* **28**: 424–428.
127. **Kazuno, T. and Mori, A.** 1954. The synthesis of trihydroxycoprostanane. *Proc. Japan Acad.* **30**: 486–487.
128. **Kazuno, T., Komatsubara, T. and Baba, T.** 1954. The partial synthesis of bisnorsterocholic acid. *Proc. Japan Acad.* **30**: 987–990.
129. **Kazuno, T., Mori, A. and Goto, T.** 1955. The partial synthesis of bisnorsterocholic acid by Kolbe electrolytic reaction. *J. Biochem.* **42**: 77–80
130. **Kazuno, T., Masui, T. and Hoshita, T.** 1961. Isolation of a new bile sterol, 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 26-tetrahydroxy- $\Delta$ <sup>23</sup>-bishomocholene, from bullfrog bile. *J. Biochem.* **50**: 12–19.
131. **Kazuno, T., Betsuki, S., Tanaka, Y. and Hoshita, T.** 1965. Studies on bile of *Rana nigromaculata*. *J. Biochem.* **58**: 243–247.
132. **Kazuno, T., Masui, T. and Okuda, K.** 1965. The isolation and the chemistry of a new bile alcohol, 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 26-pentahydroxybishomocholane from *Rana catesbiana* bile. *J. Biochem.* **57**: 75–80.
133. **Kibe, A., Nakai, S., Kuramoto, T. and Hoshita, T.** 1980. Occurrence of bile alcohols in the bile of a patient with cholestasis. *J. Lipid Res.* **21**: 594–599.
134. **Kibe, A., Fukura, M., Kihira, K., Kuramoto, T. and Hoshita, T.** 1981. Metabolism of bile alcohols, 24-nor-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25-tetrol and 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-26, 27-dinor-5 $\beta$ -cholestan-24-one, in rats. *J. Biochem.* **89**: 369–377.
135. **Kihira, K., Kuramoto, T. and Hoshita, T.** 1976. New bile alcohols-- Synthesis of (22R)- and (22S)-5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 22, 25-pentols. *Steroids* **27**: 383–393.
136. **Kihira, K., Yasuhara, M., Kuramoto, T. and Hoshita, T.** 1977. New bile alcohols, 5 $\alpha$ - and 5 $\beta$ -dermophols from amphibians. *Tetrahedron Lett.* 687–690.
137. **Kihira, K., Une, M., Kuramoto, T. and Hoshita, T.** 1979. Synthesis of 5 $\alpha$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26, 27-hexol. *Hiroshima J. Med. Sci.* **28**: 167–172.
138. **Kihira, K., Batta, A.K., Mosbach, E.H. and Salen, G.** 1979. Reverse cross-coupling in the synthesis of 3 $\alpha$ , 7 $\alpha$ -dihydroxy-5 $\beta$ -cholestanoic acid. *J. Lipid Res.* **20**: 421–427.
139. **Kihira, K., Morioka, Y. and Hoshita, T.** 1981. Synthesis of (22R and 22S)-3 $\alpha$ , 7 $\alpha$ , 22-trihydroxy-5 $\beta$ -cholan-24-oic acids and structure of haemulcholic acid, a unique bile acid isolated from fish bile. *J. Lipid Res.* **22**: 1181–1187.
140. **Kihira, K., Ohira, S., Kuramoto, M., Kuramoto, J., Nakayama, M. and Hoshita, T.** 1982. Configuration at C-23 in 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23-tetrol excreted by patients with cerebrotendinous xanthomatosis. *Chem. Pharm. Bull.* **30**: 3040–3041.
141. **Kihira, K., Kubota, A. and Hoshita, T.** 1984. Absolute configuration at a carbon 23 of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23, 25-pentol excreted by patients with cerebrotendinous xanthomatosis. *J. Lipid Res.* **25**: 871–875.
142. **Kihira, K., Akashi, Y., Kuroki, S., Yanagisawa,**

- J., Nakayama, F. and Hoshita, T.** 1984. Bile salts of the coelacanth, *Latimeria chalumnae*. *J. Lipid Res.* **25**: 1330–1336.
143. **Kihira, K. and Hoshita, T.** 1985. Synthesis of  $\alpha,\beta$ -unsaturated  $C_{24}$ -bile acids. *Steroids* **46**: 767–774.
144. **Kihira, K., Shimazu, K., Kuwabara, M., Yoshii, M., Takeuchi, H., Nakano, I., Ozawa, S., Onuki, M., Hatta, Y. and Hoshita, T.** 1986. Bile acid profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis. *Steroids* **48**: 109–119.
145. **Kihira, K., Noma, Y., Tsuda, K., Watanabe, T., Yamamoto, Y., Une, M. and Hoshita, T.** 1986. Absolute configuration at C-24 of  $5\beta$ -ranol, a principal bile alcohol of the bullfrog. *J. Lipid Res.* **27**: 393–397.
146. **Kihira, K., Kosaka, D., Une, M., Hiraoka, T., Kajiyama, G. and Hoshita, T.** 1987. Syntheses of deuterium labeled bile alcohols. *J. Label. Comp. Radiopharm.* **24**: 1421–1428.
147. **Kihira, K., Okamoto, A. and Hoshita, T.** 1987. Identification of new  $C_{27}$  and  $C_{24}$  bile acids in the bile of *Alligator mississippiensis*. *J. Biochem.* **101**: 1377–1384.
148. **Kihira, K., Yoshii, M., Okamoto, A., Ikawa, S., Ishii, H. and Hoshita, T.** 1990. Synthesis of new bile salt analogues, sodium  $3\alpha, 7\alpha$ -dihydroxy- $5\beta$ -cholane-24-sulfonate and sodium  $3\alpha, 7\beta$ -dihydroxy- $5\beta$ -cholane-24-sulfonate. *J. Lipid Res.* **31**: 1323–1326.
149. **Kihira, K., Fukuda, K., Kuramoto, T., Kuriyama, M., Fujiyama, J., Osame, M. and Hoshita, T.** 1991. Identification of (23S)- $5\alpha$ -cholestane- $3\alpha, 7\alpha, 12\alpha, 23, 25$ -pentol in urine of patients with cerebrotendinous xanthomatosis. *Steroids* **56**: 464–468.
150. **Kihira, K., Mikami, T., Ikawa, S., Okamoto, A., Yoshii, M., Miki, S., Mosbach, E.H. and Hoshita, T.** 1992. Synthesis of sulfonate analogs of bile acids. *Steroids* **57**: 193–198.
151. **Kimura, T. and Sugiyama, G.** 1939. Über den Abbau der Hyodesoxycholsäure zur Bisnorhyodesoxycholsäure und 6-Oxypregnanol-3-on-20. *J. Biochem.* **29**: 409–419.
152. **Kinoshita, T., Miyata, M., Ismail, S.M., Fujimoto, Y., Kakinuma, K., Ikekawa, N. and Morisaki, M.** 1988. Synthesis and determination of stereochemistry of four diastereoisomers at the C-24 and C-25 positions of  $3\alpha, 7\alpha, 12\alpha, 24$ -tetrahydroxy- $5\beta$ -cholestan-26-oic acid. *Chem. Pharm. Bull.* **36**: 134–141.
153. **Komatsubara, T.** 1954. The synthesis of trihydroxynorcholane. *Proc. Japan Acad.* **30**: 488–491.
154. **Komatsubara, T.** 1954. On the bile acid of *Rana nigromaculata nigromaculata*. *Proc. Japan Acad.* **30**: 614–617.
155. **Komatsubara, T.** 1954. The synthesis of  $3(\alpha), 7(\alpha), 12(\alpha)$ -trihydroxycoprostanic acid. *Proc. Japan Acad.* **30**: 618–621.
156. **Koopman, B.J., Wolthers, B.G., van der Molen, J.C., Nagel, G.T. and Kruizinga, W.** 1987. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. *Biochim. Biophys. Acta* **917**: 238–246.
157. **Kosaka, D., Hiraoka, T., Kohda, T., Kajiyama, G., Yamauchi, T., Kihira, K., Kuramoto, T. and Hoshita, T.** 1991. Stable isotope dilution assay for  $5\beta$ -cholestane- $3\alpha, 7\alpha, 12\alpha, 25$ -tetrol and  $5\beta$ -cholestane- $3\alpha, 7\alpha, 12\alpha, 23, 25$ -pentol in human serum using [26, 27- $D_6$ ] labeled internal standards; a highly accurate approach to the serological diagnosis of cerebrotendinous xanthomatosis. *Clin. Chim. Acta* **199**: 83–89.
158. **Kouchi, M.** 1964. Studies on the bile of shark, *Mustelus manazo*. *Hiroshima J. Med. Sci.* **13**: 341–350.
159. **Kritchevsky, D., Davidson, L.M., Mosbach, E.H. and Cohen, B.I.** 1981. Identification of acidic steroids in feces of monkeys fed  $\beta$ -sitosterol. *Lipids* **16**: 77–78.
160. **Kuramoto, T. and Hoshita, T.** 1972. The identification of  $C_{27}$ -bile acids in kite bile. *J. Biochem.* **72**: 199–201.
161. **Kuramoto, T., Kikuchi, H., Sanemori, H. and Hoshita, T.** 1973. Bile salts of anura. *Chem. Pharm. Bull.* **21**: 952–959.
162. **Kuramoto, T., Itakura, S. and Hoshita, T.** 1974. Studies on the conversion of mevalonate into bile acids and bile alcohols in toad and the stereospecific hydroxylation at carbon atom 26 during bile alcohol biogenesis. *J. Biochem.* **75**: 853–859.
163. **Kuramoto, T., Cohen, B.I. and Mosbach, E.H.** 1977. New bile alcohols II: Synthesis and mass spectra of  $C_{26}$  bile alcohols. *J. Am. Oil Chem. Soc.* **54**: 578–581.
164. **Kuramoto, T., Cohen, B.I., Rothschild, M.A., Donor, D.A. and Mosbach, E.H.** 1978. Chemical synthesis of  $5\beta$ -cholestane- $3\alpha, 7\alpha, 24, 25$ -tetrol and its metabolism in the perfused rabbit liver. *J. Biol. Chem.* **253**: 4688–4692.
165. **Kuramoto, T., Matsumoto, N. and Hoshita, T.** 1978. Syntheses of 22- and 23-hydroxylated bile alcohols. *Chem. Pharm. Bull.* **26**: 2788–2792.
166. **Kuramoto, T., Kihira, K., Matsumoto, N. and Hoshita, T.** 1981. Determination of the sulfated position in  $5\beta$ -bufol sulfate by a carbon-13 nuclear magnetic resonance study. *Chem. Pharm. Bull.* **29**: 1136–1139.
167. **Kuramoto, T., Noma, Y. and Hoshita, T.** 1983. Synthesis of (24R)- and (24S)-27-nor- $5\beta$ -cholestane- $3\alpha, 7\alpha, 12\alpha, 24, 26$ -pentols. *Chem. Pharm. Bull.* **31**: 1330–1334.
168. **Kuramoto, T., Kawamoto, K., Moriwaki, S. and Hoshita, T.** 1984. Synthesis of homoursodeoxycholic acid and [11, 12- $^3H$ ]homoursodeoxycholic acid. *Steroids* **44**: 549–559.
169. **Kuramoto, T., Moriwaki, S., Kawamoto, K. and Hoshita, T.** 1987. Intestinal absorption and metabolism of homoursodeoxycholic acid in rats. *J. Pharmacobio-Dyn.* **10**: 309–316.
170. **Kuramoto, T., Furukawa, Y., Nishina, T., Sugimoto, T., Mahara, R., Tohma, M., Kihira, K. and Hoshita, T.** 1990. Identification of short side chain bile acids in urine of patients with cerebrotendinous xanthomatosis. *J. Lipid Res.* **31**: 1895–1902.

171. **Kurauti, Y. and Kazuno, T.** 1939. Tetraoxycholan, Trioxycholen und Trioxy-bis-norsterocholansäure aus der Galle von *Rana catesbina* Shaw. Z. Physiol. Chem. **262**: 53–60.
172. **Kuroki, S., Shimazu, K., Kuwabara, M., Une, M., Kihira, K., Kuramoto, T. and Hoshita, T.** 1985. Identification of bile alcohols in human bile. J. Lipid Res. **26**: 230–240.
173. **Kuroki, S., Schteingart, C.D., Hagey, L.R., Cohen, B.I., Mosbach, E.H., Rossi, S.S., Hofmann, A.F., Matoba, N., Une, M., Hoshita, T. and Odell, D.K.** 1988. Bile salts of the West Indian manatee, *Trichechus manatus latirostris*: novel bile alcohol sulfates and absence of bile acids. J. Lipid Res. **29**: 509–522.
174. **Kuwabara, M., Ushiroguchi, T., Kihira, K., Kuramoto, T. and Hoshita, T.** 1984. Identification of bile alcohols in urine from healthy humans. J. Lipid Res. **25**: 361–368.
175. **Lawson, A.M., Madigan, M.J., Shortland, D. and Clayton, P.T.** 1986. Rapid diagnosis of Zellweger syndrome and infantile Refsum's disease by fast atom bombardment-mass spectrometry of urine bile salts. Clin. Chim. Acta **161**: 221–231.
176. **Lester, R., Pyrek, J.S., Little, J.M. and Adcock, E.W.** 1983. What is meant by the term "bile acid"? Am. J. Physiol. **244**: G107–G110.
177. **Ludwig-Kohn, H., Henning, H.V., Sziedat, A., Matthaei, D., Spittler, G., Reiner, J. and Egger, H.J.** 1983. The identification of urinary bile alcohols by gas chromatography-mass spectrometry in patients with liver disease and in healthy individuals. Eur. J. Clin. Invest. **13**: 91–98.
178. **Mabuti, H.** 1941. Über Trioxy-bisnor-sterocholansäure  $C_{26}H_{44}O_5$  aus der Galle von *Rana catesbina* Shaw. J. Biochem. **33**: 117–130.
179. **Masui, T.** 1963. Isolation of  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $\Delta^{24}$ -homo- $5\alpha$ -cholene from bullfrog bile. J. Biochem. **54**: 41–46.
180. **Masui, T. and Staple, E.** 1967. The separation of the stereo-isomers of bile steroids,  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $24\alpha$ -tetrol and  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $24\beta$ -tetrol, by thin layer chromatography. Steroids **9**: 443–450.
181. **Mathis, R.K., Watkins, J.B., Szczepanik-Van Leeuwen, P. and Lott, I.T.** 1980. Liver in the cerebro-hepato-renal syndrome: Defective bile acid synthesis and abnormal mitochondria. Gastroenterology **79**: 1311–1317.
182. **Matoba, N., Une, M. and Hoshita, T.** 1986. Identification of unconjugated bile acids in human bile. J. Lipid Res. **27**: 1154–1162.
183. **Matschiner, J.T.** 1971. Naturally occurring bile acids and alcohols and their origins. p. 11–46. In Nair, P.P. and Kritchevsky, D. (eds.), The bile acids. Vol. 1, Plenum Press, New York.
184. **Mendelsohn, D. and Mendersohn, L.** 1969. The catabolism of cholesterol in vitro. Formation of  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\beta$ -cholestanoic acid from cholesterol by rat liver. Biochem. J. **114**: 1–3.
185. **Mitra, M.N. and Elliott, W.H.** 1968. Bile acids. XXIII. A new direct synthesis of allcholic acid and its  $3\beta$  isomer. J. Org. Chem. **33**: 175–181.
186. **Moffett, R.B., Stafford, J.E., Linsk, J. and Hoehn, W.M.** 1946. Degradation of hyodesoxycholic acid. J. Am. Chem. Soc. **68**: 1857–1860.
187. **Monnens, L., Bakkeren, J., Parmentier, G., Janssen, G., van Haelst, U., Trijbels, F. and Eyssen, H.** 1980. Disturbances in bile acid metabolism of infants with the Zellweger (Cerebro-hepato-renal) syndrome. Eur. J. Pediat. **133**: 31–35.
188. **Morimoto, K.** 1964. The synthesis of trihydroxy-24-ethyl-coprostanic acid and chromatography of stero-bile acids. J. Biochem. **55**: 410–414.
189. **Morimoto, K., Kurata, Y., Hoshita, N. and Okuda, K.** 1968. Partial synthesis of stero-bile acids related to lithocholic acid. Hiroshima J. Med. Sci. **17**: 1–6.
190. **Morsman, H., Steiger, M. and Reichstein, T.** 1937. Abbau der Cholsäure zu  $3$ ,  $7$ ,  $12$ -Trioxy-pregnan-20-on. Helv. Chim. Acta **20**: 3–16.
191. **Moss, G.P.** 1989. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). The nomenclature of steroids. Recommendations 1989. Eur. J. Biochem. **186**: 429–458.
192. **Mui, M.M., Kamat, S.Y. and Elliott, W.H.** 1974. Bile acids XLII. Preparation of  $5\alpha$ -cholestan-26-oic acids from kryptogenin. Steroids **24**: 239–250.
193. **Murata, M., Kuramoto, T. and Hoshita, T.** 1978. Identification of bile alcohols in normal rabbit bile. Steroids **31**: 319–332.
194. **Nagata, K., Takakura, K., Asano, T., Seyama, Y., Hirota, H., Shigematsu, N., Shima, I., Kasama, T. and Shimizu, T.** 1992. Identification of  $7\alpha$ -hydroxy-3-oxo-4-cholestenoic acid in chronic subdural hematoma. Biochim. Biophys. Acta **1126**: 229–236.
195. **Nakatomi, F., Kihira, K., Kuramoto, T. and Hoshita, T.** 1985. Intestinal absorption and metabolism of norcholic acid in rats. J. Pharmacobio-Dyn. **8**: 557–563.
196. **Noll, B.W., Doisy, Jr., E.A. and Elliott, W.H.** 1973. Bile acids. XXXIX. Metabolism of  $5\alpha$ -cholestane- $3\beta$ , 26-diol and  $5\alpha$ -cholestane- $3\beta$ ,  $7\alpha$ , 26-triol in the rat with a bile fistula. J. Lipid Res. **14**: 391–399.
197. **Noma, Y., Nama, Y., Kihira, K., Yasuhara, M., Kuramoto, T. and Hoshita, T.** 1976. Isolation of new  $C_{26}$  bile alcohols from bullfrog bile. Chem. Pharm. Bull. **24**: 2686–2691.
198. **Noma, Y., Une, M., Kihira, K., Yasuda, M., Kuramoto, T. and Hoshita, T.** 1980. Bile acids and bile alcohols of bullfrog. J. Lipid Res. **21**: 339–346.
199. **Noma, Y., Kihira, K., Kuramoto, T. and Hoshita, T.** 1988. Metabolism of  $C_{26}$  bile alcohols in the bullfrog, *Rana Catesbeiana*. Steroids **51**: 385–394.
200. **Oftebro, H., Bjorkhem, I., Skrede, S., Schreiner, A. and Pedersen, J.I.** 1980. Cerebrotendinous xanthomatosis. A defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid. J. Clin. Invest. **65**: 1418–1430.
201. **Okuda, K., Hoshita, T. and Kazuno, T.** 1962. Isolation of a new bile sterol,  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $25\xi$ , 26-pentahydroxycoprostanane from toad bile. J. Biochem. **51**: 48–55.
202. **Okuda, K., Enomoto, S., Morimoto, K. and**

- Kazuno, T.** 1962. The isolation of a new bile sterol, 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-24, 27-epoxycoprostanane, from sting-ray bile. *J. Biochem.* **51**: 441–442.
203. **Okuda, K. and Danielsson, H.** 1965. Synthesis and metabolism of 5 $\beta$ -cholestane-3 $\alpha$ ,7 $\alpha$ , 12 $\alpha$ -triol-26-al. *Acta Chem. Scand.* **19**: 2160–2165.
204. **Okuda, K., Horning, M.G. and Horning, E.C.** 1972. Isolation of a new bile acid, 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\alpha$ -cholestan-26-oic acid, from lizard bile. *J. Biochem.* **71**: 885–890.
205. **Parmentier, G.G., Janssen, G.A., Eggermont, E.A. and Eyssen, H.J.** 1979. C<sub>27</sub> bile acids in infants with coprostanic acidemia and occurrence of a 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -C<sub>29</sub> dicarboxylic bile acid as a major component in their serum. *Eur. J. Biochem.* **102**: 173–183.
206. **Parmentier, G.G., Busson, R.H., Janssen, G.A., Mannaerts, G.P. and Eyssen, H.J.** 1993. Synthesis and 29-<sup>14</sup>C-labeling of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-27-carboxymethyl-5 $\beta$ -cholestan-26-oic acid. A bile acid occurring in peroxisomal diseases. *Steroids* **58**: 351–356.
207. **Pearlman, W.H.** 1947. The preparation of C-27 steroids from bile acids. I. Coprostanetetrol-3( $\alpha$ ), 7( $\alpha$ ), 12( $\alpha$ ), 25. *J. Am. Chem. Soc.* **69**: 1475–1476.
208. **Pellicciari, R., Natalini, B., Roda, A., Machado, M.I.L. and Marinozzi, M.** 1989. Preparation and physicochemical properties of natural (23R)-3 $\alpha$ , 7 $\alpha$ , 23- and (23R)-3 $\alpha$ , 12 $\alpha$ , 23-trihydroxylated bile acids and their (23S)-epimers. *J. Chem. Soc. Perkin Trans. I.* 1289–1296.
209. **Poulos, A. and Whiting, M.J.** 1985. Identification of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid, an intermediate in cholic acid synthesis, in the plasma of patients with infantile Refsum's disease. *J. Inher. Metab. Dis.* **8**: 13–17.
210. **Pyrek, J.S., Sterzycki, R., Lester, R. and Adcock, E.** 1982. Constituents of human meconium: II. Identification of steroidal acids with 21 and 22 carbon atoms. *Lipids* **17**: 241–249.
211. **Pyrek, J.S., Little, J.M. and Lester, R.** 1984. Detection of 3-hydroxy-etianic and 3-hydroxybis-norcholanic acids in human serum. *J. Lipid Res.* **25**: 1324–1329.
212. **Radomska-Pyrek, A., Huynh, T., Lester, R. and Pyrek, J.St.** 1986. Preparation and characterization of 3-monohydroxylated bile acids of different side chain length and configuration at C-3. Novel approach to the synthesis of 24-norlithocholic acid. *J. Lipid Res.* **27**: 102–113.
213. **Riva, S., Bovara, R., Zetta, L., Pasta, P., Ottolina, G. and Carrea, G.** 1988. Enzymatic  $\alpha/\beta$  inversion of C-3 hydroxyl of bile acids and study of the effects of organic solvents on reaction rates. *J. Org. Chem.* **53**: 88–92.
214. **Ruzicka, L., Plattner, Pl.A. and Heusser, H.** 1944. Über  $\beta'$ -[3 $\alpha$ ,7 $\alpha$ ,12 $\beta$ -Trioxy-nor-cholanyl-(23)]- $\Delta^{\alpha,\beta}$ -butenolid, ein Homologes der digitaloiden Aglucone. *Helv. Chim. Acta* **27**: 186–194.
215. **Sarel, S. and Yanuka, Y.** 1959. Preparation and degradation of 3 $\alpha$ -hydroxycholic acid. *J. Org. Chem.* **24**: 2018–2019.
216. **Sasaki, T.** 1966. Comparative studies on the bile salts of fishes by thin layer chromatography. *J. Biochem.* **60**: 56–62.
217. **Schteingart, C.D. and Hofmann, A.F.** 1988. Synthesis of 24-nor-5 $\beta$ -cholan-23-oic acid derivatives: a convenient and efficient one-carbon degradation of the side chain of natural bile acids. *J. Lipid Res.* **29**: 1387–1395.
218. **Schwenk, E., Riegel, B., Moffett, R.B. and Stahl, E.** 1943. The preparation of the homologs of 3-hydroxy-12-ketocholanic acid. *J. Am. Chem. Soc.* **65**: 549–551.
219. **Seno, H.** 1954. The partial synthesis of Trihydroxy-norsterocholane. *Proc. Japan Acad.* **30**: 887–890.
220. **Setchell, K.D.R., Bragetti, P., Zimmer-Nechemias, L., Daugherty, C., Pelli, M.A., Vaccaro, R., Gentili, G., Distrutti, E., Dozzini, G., Morelli, A. and Clerici, C.** 1992. Oral bile acid treatment and the patient with Zellweger syndrome. *Hepatology* **15**: 198–207.
221. **Setoguchi, T., Salen, G., Tint, G.S. and Mosbach, E.H.** 1974. A biochemical abnormality in cerebrotendinous xanthomatosis. Implication of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain. *J. Clin. Invest.* **53**: 1393–1401.
222. **Shah, P.P., Staple, E., Shapiro, I.L. and Kritchevsky, D.** 1969. Isolation of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxycoprostanic acid from baboon bile. *Lipids* **4**: 82–83.
223. **Shalon, Y. and Elliott, W.H.** 1973. Improved aldehyde synthesis: Preparation of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -triacetoxy-5 $\beta$ -cholan-23-al with ruthenium tetroxide in neutral medium. *Syn. Commun.* **3**: 287–291.
224. **Shalon, Y. and Elliott, W.H.** 1976. Bile acids. LII. The synthesis of 24-nor-5 $\alpha$ -cholic acid and its 3 $\beta$ -isomer. *Steroids* **28**: 655–667.
225. **Shefer, S., Dayal, B., Tint, G.S., Salen, G. and Mosbach, E.H.** 1975. Identification of pentahydroxy bile alcohols in cerebrotendinous xanthomatosis: characterization of 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ , 25-pentol and 5 $\beta$ -cholestane-3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 23 $\xi$ , 25-pentol. *J. Lipid Res.* **16**: 280–286.
226. **Shimazu, K., Kuwabara, M., Yoshii, M., Kihira, K., Takeuchi, H., Nakano, I., Ozawa, S., Onuki, M., Hatta, Y. and Hoshita, T.** 1986. Bile alcohol profiles in bile, urine, and feces of a patient with cerebrotendinous xanthomatosis. *J. Biochem.* **99**: 477–483.
227. **Shimizu, K., Noda, F. and Yamasaki, K.** 1958. Preparation of 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ -trihydroxy-24 $\alpha$ -oxocoprostanane and 3 $\alpha$ , 7 $\alpha$ , 12 $\alpha$ , 24 $\xi$ -tetrahydroxycoprostanane. *J. Biochem.* **45**: 625–627.
228. **Shimizu, T. and Oda, T.** 1934. Untersuchung der Krotengalle. II. Trioxy-bufo-sterocholensaure C<sub>28</sub>H<sub>46</sub>O<sub>5</sub> aus Wintergalle. *Z. Physiol. Chem.* **227**: 74–83.
229. **Shimizu, T. and Kazuno, T.** 1936. Über die Konstitution der Trioxy-bufo-sterocholensaure und den systematischen Abbau der Cholsaure. *V. Z. Physiol. Chem.* **244**: 167–172.
230. **Shoda, J., Mahara, R., Osuga, T., Tohma, M., Ohnishi, S., Miyazaki, H., Tanaka, N. and Matsuzaki, Y.** 1988. Similarity of unusual bile acids in human umbilical cord blood and amniotic fluid from newborns and in sera and urine from

- adult patients with cholestatic liver diseases. 1988. *J. Lipid Res.* **29**: 847–858.
231. **Stellaard, F., Kleijer, W.J., Wanders, R.J.A., Schutgens, R.B.H. and Jakobs, C.** 1991. Bile acids in amniotic fluid: promising metabolites for the prenatal diagnosis of peroxisomal disorders. *J. Inher. Metab. Dis.* **14**: 353–356.
232. **Svoboda, J.A., Thompson, M.J. and Robbins, W.E.** 1968.  $3\beta$ -Hydroxy-24-norchol-5-en-23-oic acid—A new inhibitor of the  $\Delta^{24}$ -sterol reductase enzyme system(s) in the tobacco hornworm, *Manduca sexta* (Johannson). *Steroids* **12**: 559–570.
233. **Takamori, M.** 1953 The synthesis of the derivatives of norcholic acid. *Hiroshima Igaku* (in Japanese) **6**: 320–322.
234. **Takamori, M.** 1953 The synthesis of the derivatives of bisnorcholic acid. *Hiroshima Igaku* (in Japanese) **6**: 323–325.
235. **Takeda, K., Komeno, T. and Igarashi, K.** 1954. Bile acids and steroids. VI. On the saponification of 7-oxo-6-bromocholanic acid. *Pharm. Bull.* **2**: 352–358.
236. **Thomassen, P.A.** 1979. Urinary bile acids during development of recurrent cholestasis of pregnancy. *Eur. J. Clin. Invest.* **9**: 417–423.
237. **Tint, G.S., Dayal, B., Batta, A.K., Shefer, S., Joanen, T. McNease, L. and Salen, G.** 1980. Biliary bile acids, bile alcohols, and sterols of *Alligator mississippiensis*. *J. Lipid Res.* **21**: 110–117.
238. **Tint, G.S., Dayal, B., Batta, A.K., Shefer, S., Joanen, T., McNease, L. and Salen, G.** 1981. The fecal bile acids and sterols of *Alligator mississippiensis*. *Gastroenterology* **80**: 114–119.
239. **Une, M., Kihira, K., Kuramoto, T. and Hoshita, T.** 1978. Two new bile alcohols, 3-epimyxinol and 3-epi-16-deoxy-myxinol from the hagfish, *Heptatretus burgeri*. *Tetrahedron Lett.* 2527–2530.
240. **Une, M., Matsumoto, N., Kihira, K., Yasuhara, M., Kuramoto, T. and Hoshita, T.** 1980. Bile salts of frogs: a new higher bile acid,  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 26-tetrahydroxy- $5\beta$ -cholestanoic acid from the bile of *Rana plancyi*. *J. Lipid Res.* **21**: 269–276.
241. **Une, M., Nagai, F., Kihira, K., Kuramoto, T. and Hoshita, T.** 1983. Synthesis of four diastereoisomers at carbons 24 and 25 of  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 24-tetrahydroxy- $5\beta$ -cholestan-26-oic acid, intermediates of bile acid biosynthesis. *J. Lipid Res.* **24**: 924–929.
242. **Une, M., Kuramoto, T. and Hoshita, T.** 1983. The minor bile acids of the toad, *Bufo vulgaris formosus*. *J. Lipid Res.* **24**: 1468–1474.
243. **Une, M., Nagai, F. and Hoshita, T.** 1983. High-performance liquid chromatographic separation of higher bile acids. *J. Chromatogr.* **257**: 411–415.
244. **Une, M., Morigami, I., Kihira, K. and Hoshita, T.** 1984. Stereospecific formation of (24E)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\beta$ -cholest-24-en-26-oic acid and (24R, 25S)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 24-tetrahydroxy- $5\beta$ -cholestan-26-oic acid from either (25R)- or (25S)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\beta$ -cholestan-26-oic acid by rat liver homogenate. *J. Biochem.* **96**: 1103–1107.
245. **Une, M., Shinonaga, Y., Matoba, N., Kuroki, S., Kihira, K. and Hoshita, T.** 1986. Identification of new bile alcohols,  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $24$ , 26-tetrol,  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $25$ ,  $26$ -tetrol, and  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $26$ ,  $27$ -tetrol in human gallbladder bile. *J. Lipid Res.* **27**: 1318–1323.
246. **Une, M., Tazawa, Y., Tada, K. and Hoshita, T.** 1987. Occurrence of both (25R)- and (25S)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\beta$ -cholestanoic acids in urine from an infant with Zellweger's syndrome. *J. Biochem.* **102**: 1525–1530.
247. **Une, M., Tsujimura, K., Kihira, K. and Hoshita, T.** 1989. Identification of (22R)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $22$ - and (23R)- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $23$ -tetrahydroxy- $5\beta$ -cholestanoic acids in urine from a patient with Zellweger's syndrome. *J. Lipid Res.* **30**: 541–547.
248. **Une, M., Kisaka, N., Yoshii, M. and Hoshita, T.** 1989. Identification of  $3\alpha$ ,  $6\alpha$ ,  $7\alpha$ ,  $12\alpha$ -tetrahydroxy- $5\beta$ -cholestanoic acid in Zellweger's syndrome. *J. Biochem.* **106**: 501–504.
249. **Wanders, R.J.A., Casteels, M., Mannaerts, G.P., Van Roermund, C.W.T., Schutgens, R.B.H., Kozich, V., Zeman, J. and Hyaneck, J.** 1991. Accumulation and impaired in vivo metabolism of di- and trihydroxycholestanoic acid in two patients. *Clin. Chim. Acta* **202**: 123–132.
250. **Wessely, F. and Swoboda, W.** 1951. Über die Reduktion Gallensauren und ihrer Amide mit Lithiumaluminiumhydrid. *Monatsh. Chem.* **82**: 437–442.
251. **Wolthers, B.G., Volmer, M., van der Molen, J., Koopman, B.J., de Jager, A.E.J. and Waterreus, R.J.** 1983. Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography. *Clin. Chim. Acta* **131**: 53–65.
252. **Yamasaki, K. and Yuuki, M.** 1936. Über die Gallensaure der Alligatorschildkroten. *Z. Physiol. Chem.* **244**: 173–180.
253. **Yanuka, Y., Katz, R. and Sarel, S.** 1968. Bile acid chemistry. III. Stepwise side-chain shortening by way of sodium per-iodate oxidation of  $\alpha$ -hydroxy bile acids into corresponding aldehydes. *Tetrahedron Lett.* 1725–1728.
254. **Yashima, H.** 1963. Synthesis and metabolism of cholic aldehyde. *J. Biochem.* **54**: 47–50.
255. **Yasuhara, M., Kuramoto, T. and Hoshita, T.** 1978. Identification of  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $23\beta$ -tetrol,  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $24\alpha$ -tetrol, and  $5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ ,  $24\beta$ -tetrol in cerebrotendinous xanthomatosis. *Steroids* **31**: 333–345.
256. **Yoshii, M., Une, M., Kihira, K., Kuramoto, T. and Hoshita, T.** 1989. Synthesis of  $5\beta$ -cholestane- $3\alpha$ ,  $6\beta$ ,  $7\alpha$ ,  $25$ ,  $26$ -pentol and identification of a novel bile alcohol,  $\alpha$ -trichechol, present in the West Indian manatee bile. *Chem. Pharm. Bull.* **37**: 1852–1854.
257. **Yoshii, M., Une, M., Kihira, K., Kuramoto, T., Akizawa, T., Yoshioka, M., Butler, Jr. V.P. and Hoshita, T.** 1994. Bile salts of the toad, *Bufo marinus*, characterization of a new unsaturated higher bile acid,  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 26-tetrahydroxy- $5\beta$ -cholest-23-en-27-oic acid. *J. Lipid Res.* **35**: in press.